

Ministry of Higher Education and Scientific Research
Ibn Khaldoun University - Tiaret
Faculty of Natural and Life Sciences
Department of Biology

Pedagogical Support

HEMATOLOGY





Prepared by

Dr. BOUDRA Abdellatif

Associate Professor "A"

List of abbreviations

- **RBCs**: Red Blood Cells
- **MCHC**: Mean Corpuscular Hemoglobin Concentration
- **CCMH**: Corpuscular Concentration of Hemoglobin
- **Hct**: Hematocrit
- **Hb**: Hemoglobin
- **CBC**: Complete Blood Count
- **WBCs**: White Blood Cells
- **PT**: Prothrombin Time
- **PTT**: Partial Thromboplastin Time
- **G-CSF**: Granulocyte Colony-Stimulating Factor
- **IL**: Interleukin
- **CFU-E**: Colony-Forming Unit, Erythroid
- **BFU-E**: Burst-Forming Unit, Erythroid
- **TPO**: Thrombopoietin
- **HSCs**: Hematopoietic Stem Cells
- **PCs**: Platelet Concentrates
- **APCs**: Apheresis Platelet Concentrates
- **FFP**: Fresh Frozen Plasma
- **MDS**: Myelodysplastic Syndromes
- **CBC**: Complete Blood Count
- **HDN**: Hemolytic Disease of the Newborn
- **WBCs**: White Blood Cells
- BFU-E*rming Unit, Erythroid
- **GM-CSF**: Granulphage Colony-Stimulating Factor
- G-CSF: Granulocyte Colony-Stimulating Factor
- **SCF**: Stem Cell Factor (a cytokine that promotes hematopoietic stem cell survival
- **CXCR4**: C-X-C Chemokine Receptor Type 4 (receptor involved in stem cell homing and mobilization)
- **VCAM-1**: Vascular Cell Adhesion Molecule 1 (important in the adhesion of hematopoietic stem cells to the bone marrow niche)
- **TBI**: Total Body Irradiation (used in conditioning regimens before stem cell transplantation)
- **GVL**: Graft-versus-Leukemia (immune response triggered by donor stem cells against leukemia cells)
- **BMT**: Bone Marrow Transplant (a procedure to treat hematologic diseases by transplanting hematopoietic stem cells)
- **CFU-GEMM**: Colony Forming Unit - Granulocyte, Erythrocyte, Monocyte, Megakaryocyte (a progenitor cell that can differentiate into various blood cell types)
- **CFU-E**: Colony-Forming Unit, Erythroid
- **MDS**: Myelodysplastic Syndromes
- **IL-3**: Interleukin-3
- **TBI**: Total Body Irradiation
- **HSC**: Hematopoietic Stem Cells

List of figures and tables

Figures

Figure 1 : Site of haemopoiesis.....5
Figure 2 : ERYTHROPOIESIS.....16
Figure3: Platelets.....17
Figure 4: The structure of a heme, with an iron atom at its center like a jewel, which binds oxygen (O_2).....19
Figure 5:Hemoglobin.....20
Figure 6 : Neutrophil.....23
Figure 7: Eosinophil.....25
Figure 8: Basophil.....27
Figure 9: Mast Cells.....28
Figure 10: Monocyte.....30
Figure 11: Macrophage.....32
Figure 12: Monocyte and macrophage.....33
Figure13 : Megakaryopoiesis and thrombopoiesis process.....36
Figure14 : NK Cells.....41
Figure15 : differentiation of hematopoietic stem cells.....44

Tables

Table 1 Sites of haemopoiesis.....6

Table of contents

List of abbreviations
List of figures and tables
Presentation of the Hematology Module....1
1-Introduction 2
1.1.Basic concepts of hematology....3
2.Hematopoietic system....4
3.Site of haemopoiesis....4
4.Blood composition and functions....6
5.Cellular components of blood....6
6.Blood grouping procedure....7
6.1.Preparation of reagents....7
6.2. Reaction with antibodies....7
6.3.Observation....7
7. Plasma components....8
8. Stromal cells....8
9.Hematopoietic stem cells....8
10.Homing and mobilization of hematopoietic stem cells (hscs)....9
10.1.Homing of hscs....9
10.2.Mobilization of hscs....10
10.3.Interplay between homing and mobilization....10
10.4.Clinical applications....10
11.Progenitor and precursor....11
12. Balance between self-renewal and differentiation in normal hematopoiesis....12
13. Maturation process....12
13.1. Common and general morphological changes linked to maturation....12
1. Reduction in cell size....12
2. Reduction in nuclear-to-cytoplasmic ratio....13
3. Disappearance of nucleoli....13
4. Chromatin condensation....13
13.2. Specific maturation features in different lineages....13
1. Nuclear changes....13
2. Cytoplasmic changes....14
3. Membrane changes....14
14. Erythropoiesis....15
14.1. Energy metabolism....17
14.3. Hemoglobin....18
14.4.Red blood cell....21
15. Myelopoiesis....21

15.1. Myelopoiesis and granulocyte development.....21
1. Neutrophil.....22
2. Eosinophils.....24
3. Basophils.....26
16. Mast cells.....28
17. Monocytes and macrophages.....29
18. Dendritic cells.....34
19. Megakaryopoiesis and platelet formation.....34
19.1. Megakaryopoiesis.....34
19.2. Thrombopoiesis.....35
19.3. Hemostasis and coagulation.....35
20. Lymphatic tissues and immune response.....37
20.1. Primary lymphoid organs.....37
20.2. Secondary lymphoid organs.....37
20.3.functions of lymphoid organs.....38
21. B-lymphocytes.....38
21.1. T-lymphocytes.....39
22. Natural killer (nk) cells.....40
22.1.key features of nk cells.....42
22.2.nk cell regulation by mhc molecules.....43
23. Bone marrow and peripheral blood consequences of consumption and deficient production of hematopoietic cells (erythrocytes, neutrophils, platelets).....45
23.1. Reminder: key blood test parameters and their implications for red blood cell function and anemia diagnosis.....45
23.2. Consequences of the consumption of hematopoietic cells.....47
23.3.Clinical examples.....48
23.4.Different types of anemia and their details.....48
23.4.Treatment of anemia.....52
23.5.General management.....55
24.Thrombocytopenia and pregnancy.....55
25.Importance of blood smear and its technique: preparation and mgg staining.....56
25.1.Preparation of blood smear.....56
25.2. Staining the blood smear: mgg (may-grünwald giemsa) staining.....57
25.3. Advantages of mgg staining.....58
26.Blood transfusion.....59
26.1. Labile blood products (LBP).....59
26.2.Development of labile blood products.....61
26.3.Biological screening of blood donations.....62
27.Process of blood donation screening and donation disposal.....63
27.2.Ethical aspects related to blood donor rights in algeria.....64
27.2.Main contraindications for blood donation in france.....66
28.Hematology transplants.....67

28.1.Allograft.....68
28.2.Autograft.....69
28.3.Peripheral hematopoietic stem cells.....70
28.4.Cord blood.....71
28.5.Quality control.....71
28.6.Complications.....72
29.Recommendations and guidelines for future students considering a career in hematology.....73
30.Safety recommendations for future students pursuing a career in hematology.....78
31.Useful terminolofy 79
31.1.Basic terms.....78
31.2.Blood disorders.....78
31.3.Laboratory tests.....78
31.4.Clotting factors.....79
31.5.Transudate and exudate.....79
31.6.Serum and Plasma.....83
31.7.Additional informations.....83

References 97



Presentation of the Hematology Module

Hematology is a crucial field within biological sciences that focuses on the study of blood, its components, and related disorders. In the context of this course, students will gain a thorough understanding of the structure, function, and development of blood cells, as well as the various physiological processes that regulate blood formation and circulation. As future professionals in parasitology, students will explore how blood-related conditions, such as anemia, leukemia, and clotting disorders, can be influenced or caused by parasitic infections. The course will also cover the role of the immune system in blood health and its response to both internal and external threats, including parasitic invasions.

The primary objectives of this course are to equip students with the knowledge required to identify and analyze different blood disorders, understand the mechanisms behind these disorders, and recognize the interplay between parasitic diseases and hematological changes. Students will also develop the ability to diagnose and interpret hematological abnormalities in the context of parasitic diseases, which is essential for their future careers in research and clinical practice. This module ties directly into the broader parasitology curriculum, allowing students to link hematological knowledge with the study of parasitic pathogens and their impact on the host organism, thus providing a holistic view of how blood health is compromised by infectious agents. Upon completion of the course, students will be better prepared to apply their hematological understanding to both theoretical and practical aspects of parasitology, enabling them to contribute to the advancement of medical and biological research in this area.



1-Introduction

Hematology is a specialized branch of medicine that focuses on the study of blood, the organs involved in its production (such as the bone marrow), and various blood-related diseases. This field encompasses an in-depth understanding of the structure and function of blood components, including red blood cells (RBCs), white blood cells (WBCs), platelets, and the process of hematopoiesis, which is the production of blood cells from stem cells in the bone marrow. Hematology is essential in diagnosing, treating, and managing a wide range of hematological disorders, including anemias, leukemias, lymphomas, hemophilia, and blood clotting disorders like hemophilia and deep vein thrombosis (DVT).

The study of blood cells is central to hematology. Red blood cells, which carry oxygen to tissues and remove carbon dioxide, are crucial for maintaining life. Any disruptions in the production, function, or lifespan of RBCs can lead to conditions like anemia, where the body does not have enough healthy RBCs, leading to fatigue and other symptoms. White blood cells are responsible for defending the body against infections, and abnormalities in their number or function can lead to disorders such as leukemia (a type of cancer affecting blood cells) or lymphoma (cancer of the lymphatic system). Platelets, on the other hand, are involved in blood clotting, and abnormalities can result in bleeding disorders like hemophilia or thrombocytopenia (low platelet count), which make it difficult for blood to clot properly.

Hematologists are trained specialists who focus on diagnosing and managing these conditions. They employ a range of diagnostic tools, including blood tests, bone marrow biopsies, and genetic analysis, to detect abnormalities in blood cells or coagulation pathways. Treatment strategies in hematology may include chemotherapy, bone marrow transplants, blood transfusions, gene therapy, and medications aimed at correcting underlying blood disorders. For example, in leukemia, chemotherapy is commonly used to target cancerous white blood cells, while blood transfusions are often used to treat conditions like sickle cell anemia or thalassemia, where patients suffer from chronic anemia.

The field also involves transfusion medicine, which focuses on the safe collection, processing, and transfusion of blood and its components (such as red blood cells, platelets, and plasma). Blood banking is a critical part of hematology, as it ensures a reliable supply of blood for patients undergoing surgery, trauma, or treatment for blood disorders. Hematologists must also be knowledgeable about bone marrow disorders,



including myelodysplastic syndromes and myeloproliferative disorders, which affect the production of blood cells in the bone marrow.

In addition to clinical practice, hematology is an important area of medical research. Researchers in this field focus on advancing our understanding of blood-related diseases at the molecular level, seeking new therapies and developing more effective treatments for conditions like sickle cell disease, leukemia, and lymphoma. Current studies explore cutting-edge topics such as gene editing, immunotherapy, and regenerative medicine, which offer the potential for curing genetic blood disorders or reprogramming the immune system to better target and destroy cancerous cells.

In summary, hematology is a vital branch of medicine that addresses a broad spectrum of disorders affecting blood cells, blood clotting, and the organs involved in blood production. Hematologists play a crucial role in the diagnosis, treatment, and management of these conditions, and their work has significant implications for both patient care and ongoing medical research. Through their efforts, advancements in treatment options and life-saving therapies continue to improve, enhancing the quality of life for individuals suffering from hematological diseases.

1.1.Basic concepts of hematology

Hematology is the scientific study of blood, its components, and the disorders that affect it. Blood is made up of plasma, red blood cells (RBCs), white blood cells (WBCs)**,** and platelets, each with specific functions vital to maintaining health. RBCs are responsible for transporting oxygen throughout the body, WBCs play a key role in the immune system by defending against infections, and platelets are essential for blood clotting and wound healing. The process of hematopoiesis refers to the production of blood cells, primarily in the bone marrow. Hematologists focus on diagnosing and managing various blood disorders such as anemia (deficiency of RBCs or hemoglobin), leukemia (a type of blood cancer), hemophilia (bleeding disorders), and thrombosis (abnormal blood clotting). A deep understanding of these blood components, their functions, and the processes involved in blood formation is crucial for effective diagnosis, treatment, and prevention of hematological diseases.



2.The Hematopoietic system

he hematopoietic system is responsible for the production of blood cells, a process known as hematopoiesis. It involves specialized tissues, primarily the bone marrow, where hematopoietic stem cells differentiate into various types of blood cells—red blood cells (RBCs), white blood cells (WBCs), and platelets. This system also includes the spleen and liver in fetal development and in certain disease states. Hematopoietic stem cells have the ability to self-renew and differentiate into more specialized progenitor cells, which then mature into functional blood cells. This continuous process ensures a steady supply of blood cells necessary for oxygen transport, immune defense, and blood clotting. Disruptions in the hematopoietic system can lead to a variety of blood disorders, including anemia, leukemia, and thrombocytopenia.

3.Site of haemopoiesis

During early gestation, the yolk sac is the primary site of hematopoiesis. However, definitive blood cell production originates from stem cells in the AGM (aorta-gonad-mesonephros) region, which later colonize the liver, spleen, and bone marrow. From the 6th week to 6–7 months of fetal life, the liver and spleen serve as the main hematopoietic organs until the bone marrow becomes the dominant site. In childhood and adulthood, blood cell production is restricted to the axial skeleton and the proximal ends of the femurs and humeri, while the rest of the bone marrow is replaced by fat. However, under certain conditions, fatty marrow can revert to hematopoiesis, and the liver and spleen may resume their fetal role in extramedullary hematopoiesis(Figure 1) (table1).



Figure 1 : Site of haemopoiesis



Table 1 Sites ofhaemopoiesis.

Embryonic period	**0-2 months (yolk sac)**
Fetal period	✓ 2-7 months (liver, spleen) ✓ 5-9 months (bone marrow)
Infants	✓ Bone marrow (practically all bones)
Adults	✓ Vertebrae, ribs, sternum, skull, sacrumand pelvis, proximal ends of femur

4.Blood Composition and functions

Blood is a vital fluid that circulates throughout the body, delivering oxygen and nutrients to cells, removing waste products, and playing a crucial role in immune defense, clotting, and temperature regulation. Blood consists of two main components: cellular components and plasma.

5.Cellular components of blood

Blood is composed of cellular components and plasma, each playing crucial roles in maintaining bodily functions. The cellular components include red blood cells (RBCs), which transport oxygen from the lungs to tissues and return carbon dioxide for exhalation; they are biconcave, flexible, and lack a nucleus, with a lifespan of approximately 120 days. White blood cells (WBCs) are part of the immune system, protecting the body from infections and foreign invaders, and include neutrophils, lymphocytes, monocytes, eosinophils, and basophils, each with distinct roles in immune responses. WBCs have a nucleus and can move through blood vessel walls, with lifespans ranging from a few hours to several years. Platelets (thrombocytes) are involved in blood clotting, preventing excessive bleeding by aggregating at injury sites; they are small, disc-shaped cell fragments with a lifespan of 7-10 days. Plasma, the liquid portion of blood, makes up about 55% of blood volume and consists of water, proteins (like albumin, globulins, and fibrinogen), electrolytes, nutrients (glucose, amino acids, lipids), waste products (urea, creatinine, bilirubin), hormones, and gases (oxygen and carbon dioxide). Plasma serves as a medium for transporting nutrients, hormones, gases, and waste products, and plays a key role in maintaining osmotic balance and pH regulation.



The ABO blood group system is essential for blood transfusions, organ transplants, and pregnancy, based on the presence or absence of A and B antigens on red blood cells (RBCs). The four blood types are TypeA (with A antigens and anti-B antibodies), Type B (with B antigens and anti-A antibodies), Type AB (with both A and B antigens and no anti-A or anti-B antibodies, making it the universal plasma recipient), and Type O (with no A or B antigens and anti-A and anti-B antibodies, making it the universal RBC donor). The Rh factor, another key antigen, further determines blood compatibility by identifying whether the Rh antigen is present (Rh-positive) or absent (Rh-negative). This is particularly important in pregnancy, where Rh incompatibility between an Rh-negative mother and an Rh-positive fetus can cause hemolytic disease of the newborn (HDN). Incompatible blood transfusions can result in severe immune reactions, and ABO compatibility is also crucial for preventing organ rejection in transplants. Thus, both ABO and Rh compatibility are critical for safe blood transfusions, organ transplants, and managing pregnancy-related blood issues.

6.Blood Grouping procedure:

6.1.Preparation of reagents:

Use anti-A, anti-B, and anti-Rh antibodies that specifically react with the antigens present on red blood cells.

6.2.Reaction with antibodies:

- ABO Grouping**:** On a slide or a plate, place three drops of a blood sample.
- Add anti-A reagent to the first drop.
- Add anti-B reagent to the second drop.
- Add anti-Rh reagent to the third drop (to determine Rh status).

6.3.Observation:

If agglutination (clumping) occurs, it means the corresponding antigen is present on the red blood cells.

- If agglutination occurs with the anti-A reagent, the person is blood group A.
- If agglutination occurs with the anti-B reagent, the person is blood group B.
- If agglutination occurs with both the anti-A and anti-B reagents, the person is blood group AB.
- If no agglutination occurs with both anti-A and anti-B reagents, the person is blood group O.

For the Rh factor, agglutination with the anti-Rh antibody indicates the person is Rh+, while no agglutination indicates the person is Rh-.

7. Plasma components

Plasma components in blood include proteins and factors essential for the organism's integrity. These factors are involved in coagulation, transport of various substances, and immune function. Most plasma proteins are synthesized and secreted by the liver. Through electrophoresis, plasma proteins are divided into five fractions: albumin, α1, α2, β, and γ.

Albumin is the primary protein in plasma, playing a crucial role in osmotic pressure and transporting various molecules. α1-globulins include proteins such as α1-acid glycoprotein and α1-antitrypsin. The β2-globulin fraction contains proteins like β2-macroglobulin, β2-haptoglobin (which binds free hemoglobin), ceruloplasmin, and transcobalamin. Finally, the γ-globulin fraction is rich in transferrin, an iron-binding protein, and most immunoglobulins (IgG, IgA, IgM, IgD, IgE). A global deficiency of immunoglobulins can be detected by a low or absent γ fraction in serum electrophoresis.

8. Stromal cells

he growth and differentiation of hematopoietic cells in the bone marrow are controlled by the extracellular matrix and the microenvironment provided by stromal cells. These cells, including macrophages, fibroblasts, endothelial cells, fat cells, and reticulum cells, support hematopoietic stem and progenitor cells by secreting growth factors such as GM-CSF, G-CSF, IL-6, and stem cell factor. Additionally, stromal cells release cytokines that regulate adhesion molecules on hematopoietic cells, enabling them to stay in the bone marrow or migrate to areas where specific cell types are needed.

9.Hematopoietic stem cells

Hematopoietic cells originate from pluripotent stem cells capable of self-renewal and

differentiation into all blood cell types. A single stem cell can generate progenitors for myelo, mono-, erythropoiesis, megakaryopoiesis, and lymphopoiesis, as well as stromal and dendritic cells. These stem cells are rare, making up less than 0.01% of nucleated cells in the bone marrow. They are typically dormant (G0 phase) and only divide to maintain hematopoiesis or meet the demand for progenitors. The bone marrow produces over 10^{12} blood cells daily in adults.

Stem cells express markers like CD34 and c-kit and can be enriched for transplantation. Hematopoietic growth factors primarily regulate the survival and differentiation of committed progenitor cells. Early-acting cytokines regulate primitive progenitors, while late-acting cytokines support already committed progenitors. Cytokines play a vital role in hematopoiesis.

The gene expression of early stem cells involves transcription factors like C/EBP α and Pu 1, which regulate receptors for growth factors critical for myelopoiesis. Notch receptors, found on stem cells, help maintain their undifferentiated state.

Telomeres, which shorten with each cell division, are important in stem cell aging. Adult stem cells have shorter telomeres than fetal ones, and telomere shortening occurs further after transplantation, suggesting that stem cells may not be immortal.

10.Homing and **mobilizationof hematopoietic stem cells (HSCs)**

The mechanisms of homing and mobilization of hematopoietic stem cells (HSCs) are crucial for regulating blood cell production and maintaining the balance between stem cell maintenance and differentiation. These mechanisms control the movement of HSCs between the bone marrow, where they are primarily located, and the peripheral blood, where they can be mobilized under certain physiological or therapeutic conditions.

10.1.Homing of HSCs

Homing refers to the process by which hematopoietic stem cells migrate and settle in the bone marrow, their primary site of residence. This process is regulated by complex interactions between HSCs and the bone marrow microenvironment, often referred to as the bone marrow niche. The niche consists of stromal cells, extracellular matrix components, and various growth factors that promote HSC survival, self-renewal, and differentiation. Key factors involved in HSC homing include:

- **Cytokines**, such as Stem cell factor (SCF), that promote the attachment of HSCs to the niche.
- **Adhesion molecules** (**VCAM-1**, **CXCL12**) that facilitate the physical interaction between HSCs and stromal cells.
- **Integrins** (**α4β1**) and other specific receptors that help anchor HSCs to the extracellular matrix and stromal cells.

- **Transcription factors** that regulate the expression of genes necessary for maintaining the stem cell state within the bone marrow.

10.2.Mobilization of HSCs

Mobilization refers to the process by which HSCs leave the bone marrow and enter the peripheral blood. This is especially important in hematopoietic stem cell transplantation, where HSCs are collected from the peripheral blood (after mobilization) for therapeutic purposes. Several factors influence the mobilization of HSCs:

- **Mobilizing cytokines**, such as Granulocyte Colony-Stimulating Factor (G-CSF**)** and Plerixafor (an antagonist of the CXCR4receptor), reduce the interactions between HSCs and the bone marrow niche, facilitating their release into the bloodstream.
- **Modifications to the bone marrow microenvironment**, induced by inflammatory signals or stress conditions, may reduce the affinity of HSCs for the niche and promote their release into circulation.
- **Regulation by adhesion molecules and chemotactic receptors**, such as CXCL12/CXCR4, which play a role in guiding HSCs to specific sites when needed, for example, during tissue injury or infection responses.

10.3.Interplay between homing and mobilization

The processes of homing and mobilization are dynamically regulated and interrelated. For instance, activation of G-CSF or Plerixafor signaling can trigger mobilization of HSCs by altering their interaction with the bone marrow niche, while factors like TGF-β or SCF can promote their reintegration into the bone marrow after mobilization. The niche mechanics also play a crucial role in regulating the stem cell's fate: a shift in the balance between growth signals and adhesion signals can either favor or inhibit mobilization in response to different stimuli.

10.4.Clinical applications

These mechanisms are exploited in hematopoietic stem cell transplantation, where HSC mobilization allows for the collection of stem cells from peripheral blood for transplantation after stimulation with growth factors like G-CSF or the use of agents like Plerixafor. Ongoing research aims to better understand



and manipulate these processes to improve stem cell transplant strategies, particularly in cases of **leukemia** and other hematological disorders.

In summary, the processes of homing and mobilization of hematopoietic stem cells are essential for blood cell homeostasis and regenerative capacity. A deeper understanding of these mechanisms not only enhances our comprehension of blood diseases but also enables the development of innovative therapeutic approaches, especially in the context of stem cell transplantation and treatment of hematological cancers.

11.Progenitor and precursor :

In hematopoiesis, progenitor cells are undifferentiated, multipotent cells capable of differentiating into various cell types within a specific lineage, such as red blood cells, white blood cells, or platelets. Although they can divide and produce more progenitors or precursor cells, their ability to self-renew is limited compared to stem cells. Progenitors are more differentiated than stem cells and are on a defined path toward becoming specific cell types, making them an intermediate stage between stem cells and precursor cells. Precursor cells, in contrast, are more specialized and typically unipotent, committed to a single cell fate, such as a neutrophil or erythrocyte. They have lost the ability to self-renew and are in the final stages of differentiation, acquiring the characteristics of mature cells. Precursor cells can be identified by specific markers, indicating they are one step away from becoming fully functional. Progenitors help maintain a supply of cells for differentiation, while precursors undergo final maturation to become functional blood cells. The first differentiation of a multipotent stem cell upon activation leads to two major lineages: the lymphoid stem cell and the myeloid stem cell. The lymphoid stem cell can differentiate into T lymphocytes and B lymphocytes, both critical for adaptive immune responses. The differentiation of this cell depends on specific molecular signals that guide it toward one of these lineages based on the immune system’s needs. The myeloid stem cell, also known as CFU-GEMM (Colony Forming Unit - Granulocyte, Erythrocyte, Monocyte, Megakaryocyte), gives rise to several blood cell types, including granulocytes (neutrophils, eosinophils, basophils), erythrocytes (red blood cells), monocytes, and megakaryocytes (which produce platelets). CFU-GEMM is a critical entry point in the differentiation of myeloid lineage cells, providing the foundation for the formation of blood cells essential for innate immunity and blood clotting regulation.

12.balance between self-renewal and differentiation in normal hematopoiesis

In normal hematopoiesis, there is a delicate balance between two key processes: the production of stem cells through cellular division (self-renewal) and the loss of stem cells as they commit to differentiation into specific blood cell lineages.

Self-renewal refers to the ability of hematopoietic stem cells (HSCs) to divide and produce daughter cells that maintain the stem cell pool. This process ensures a continuous supply of stem cells throughout the organism's life, thus maintaining hematopoiesis over time. It is tightly regulated to prevent exhaustion or overexpansion of the stem cell population.

On the other hand, differentiationis the process by which HSCs lose their stem cell characteristics and commit to becoming more specialized progenitor cells. These progenitor cells further differentiate into various types of blood cells, such as red blood cells, white blood cells, and platelets, depending on the body's needs. This process results in the "loss" of stem cells as they progress through the various stages of differentiation.

The balance between these two processes is critical for maintaining a steady supply of blood cells while preserving the stem cell reservoir. Disruption of this equilibrium can lead to hematopoietic disorders, such as leukemia or bone marrow failure, where either an excess or insufficient number of stem cells can lead to pathological outcomes. Therefore, maintaining proper regulation of both self-renewal and differentiation is essential for healthy hematopoiesis.

13. Maturation process:

During the maturation process, various cytological stages are observed in each lineage to give rise to functional terminal cells. These stages involve specific morphological changes common to most cell types, and they are particularly noticeable in hematopoietic cells as they mature into their final functional forms.

13.1. Common and general morphological changes linked to maturation:

5. **Reduction in cell size:**

- A decrease in cell size is visible during the maturation of erythrocytes (red blood cells) and granulocytes(a type of white blood cell**)**. This shrinkage helps cells to become more specialized and functional as they mature.

6. **Reduction in nuclear-to-cytoplasmic ratio:**

   - This is most evident in the maturation of erythroblasts (immature red blood cells) into mature red blood cells. As cells mature, the nucleus becomes smaller and more condensed, while the cytoplasm increases, reflecting the cell's functional state.

7. **Disappearance of nucleoli:**

   - The nucleolus, a structure within the nucleus involved in ribosome production, gradually disappears as the cell matures. This change is particularly noticeable in the myeloid (granulocytic) and erythroid lineages as they mature. The absence of the nucleolus reflects the cessation of active protein synthesis associated with ribosome assembly, as the cell becomes more specialized.

8. **Chromatin condensation:**

   - Chromatin condensation is a hallmark of cell maturation. In immature cells, chromatin is relatively loose and appears light under the microscope (euchromatin), allowing for active gene transcription. As the cell matures, chromatin condenses into a more tightly packed form (heterochromatin), indicating a decrease in gene activity as the cell becomes more specialized and its functions become more defined.

13.2.Specific maturation features in different lineages:

4. **Nuclear changes:**

   - **Polylobulation**: This is a characteristic feature in the granulocytic lineage. As granulocytes mature, the nucleus becomes lobulated (divided into several lobes), which is an important marker of differentiation. This change is particularly visible in neutrophils, eosinophils, and basophils.

5. **Cytoplasmic changes:**

   - **Granulation**: As granulocytes mature, they develop specific cytoplasmic granules that contain enzymes and other substances necessary for their immune functions. The appearance of these granules marks a key stage in the maturation of the granulocyte lineage. For example:

     - **Neutrophils** develop **azurophilic granules** (which contain enzymes like myeloperoxidase).
     - **Eosinophils** contain granules that stain bright red, filled with proteins like eosinophil peroxidase.
     - **Basophils** have granules that contain histamine and heparin, important for allergic reactions.

6. **Membrane changes:**

   - As the cell matures, specific membrane proteins are expressed that are characteristic of each cell type. These membrane changes are critical for the cell's functionality and can be recognized using monoclonal antibodies. For example:

     - **Red blood cells (RBCs)** will express the Rh antigenand other surface markers.
     - **T lymphocytes** will express CD3 and CD4(or CD8depending on differentiation).
     - **B lymphocytes** will express CD19 as a marker of their identity.

During erythropoiesis, red blood cell maturation is marked by the gradual loss of the nucleus in the final stages. The reticulocyte, just before becoming a mature erythrocyte, retains some ribosomal RNA but loses the nucleus, thereby becoming a functional red blood cell. In myelopoiesis, granulocyte maturation involves nuclear lobulation and the development of cytoplasmic granules. Granulocyte precursors, such as myeloblasts and promyelocytes, evolve into neutrophils, eosinophils, and basophils, with each type developing distinct functional features, including different types of granules. Lastly, in thrombopoiesis, platelets are derived from megakaryocytes, which undergo endomitosis, a process of DNA replication without cell division, resulting in large multinucleated cells. These megakaryocytes form proplatelets, which fragment to create small, functional platelets that are essential for blood clotting.

14. ERYTHROPOIESIS

Red blood cells are specialized to deliver oxygen to tissues and remove carbon dioxide from the body. The process of erythropoiesis, or red blood cell production, involves a series of gene activities leading to the formation of mature cells. It begins with a multipotent stem cell, which undergoes differentiation and commitment through several stages:

1. Stem cell
2. BFU-E (burst-forming unit, erythroid – an immature erythroid progenitor)
3. CFU-E (colony-forming unit, erythroid – a more mature progenitor)
4. Proerythroblasts, erythroblasts, and normoblasts (precursors with a nucleus that divide and gradually reduce in size as hemoglobin content increases)
5. Reticulocytes, which mature into erythrocytes (mature red blood cells)

Reticulocytes still contain remnants of ribosomal RNA, while mature erythrocytes lack a nucleus. Most nucleated red cell precursors are confined to the bone marrow. One proerythroblast can give rise to 12–16 mature red blood cells in 5–10 days.

Erythropoiesis is regulated by cytokines such as stem cell factor, IL-3, GM-CSF, and particularly erythropoietin. Erythropoietin is the primary cytokine that adjusts red blood cell production according to the body's needs. It increases the proliferation and differentiation of CFU-E and late BFU-E in response to low hemoglobin levels and tissue hypoxia. The kidneys produce more erythropoietin under these conditions, which speeds up and enhances the rate of erythropoiesis. Erythropoietin binds to specific receptors on red cell precursors, triggering further differentiation.



Figure 2 : ERYTHROPOIESIS

Red blood cells, also known as erythrocytes or hematies, are present in the blood at a concentration of approximately 4 to 6 million per cubic millimeter. They are red in color due to the binding of oxygen molecules to hemoglobin, the protein that carries oxygen throughout the body. Erythrocytes are highly deformable, allowing them to pass through the narrowest capillaries without breaking, which is crucial for efficient gas exchange. These cells are anucleate (lack a nucleus), a feature that enables more space for hemoglobin, enhancing their oxygen-carrying capacity. Erythrocytes cannot multiply in peripheral blood; they are produced in the bone marrow and circulate for about 120 days before being cleared by the spleen. The characteristic biconcave disc shape of erythrocytes, with a diameter of

approximately 8 µm and a thickness of 2 µm, increases the surface area for gas exchange and facilitates their flexibility, ensuring efficient oxygen delivery to tissues and organs throughout the body(figure2).

14.1. Energy metabolism

The red blood cell relies on its energy reserves, which gradually deplete over its lifespan. The main source of adenosine triphosphate (ATP) is provided by anaerobic glycolysis through the Embden-Meyerhof pathway, involving several enzymes, including pyruvate kinase. The primary redox system is based on the NADP-NADPH reaction, generated by the dehydrogenation of glucose-6-phosphate under the influence of glucose-6-phosphate dehydrogenase (G6PD). Any congenital enzymatic deficiency is likely to shorten the lifespan of the affected red blood cells.



Figure3: Platelets



14.3. Hemoglobin

Hemoglobin is responsible for transporting oxygen in the body. There are three main types: Hemoglobin A ($\alpha_2\beta_2$), the major adult form (96-98%); Hemoglobin F ($\alpha_2\gamma_2$), predominant during fetal development (60-80% at birth, 0.5-0.8% in adults); and Hemoglobin A2 ($\alpha_2\delta_2$), normally 1.5-3%. The hemoglobin molecule has a molecular weight of 64,500 and consists of four polypeptide chains, each carrying a heme group. Heme synthesis starts with glycine and progresses through several intermediates before iron (Fe^{2+}) binds with protoporphyrin to form heme. Hemoglobin binds oxygen, which is released into tissues in a tightly regulated process.

The oxyhemoglobin dissociation curve shows the relationship between oxygen saturation and oxygen tension. Arterial blood has an oxygen tension of 90 mmHg and a saturation of about 97%, while venous blood has lower oxygen tension (40 mmHg) and saturation (70-80%). Factors like temperature, CO_2 concentration, and 2,3-diphosphoglycerate levels affect hemoglobin's affinity for oxygen. In acidosis or high CO_2, the curve shifts right, promoting oxygen release. Increased body temperature also lowers hemoglobin’s oxygen affinity, facilitating oxygen unloading.

One molecule of hemoglobin can transport four molecules of oxygen. Each red blood cell contains approximately 250 million hemoglobin molecules, which enables each red blood cell to carry about 1 billion molecules of oxygen. Hemoglobin is a protein found in red blood cells, composed of four subunits, each capable of binding one molecule of oxygen. This high capacity for oxygen binding is essential for efficient oxygen transport from the lungs to tissues throughout the body. The ability of hemoglobin to bind and release oxygen is influenced by various factors, including the partial pressure of oxygen, pH, and the presence of carbon dioxide, which helps regulate the delivery of oxygen to where it is needed most.



Figure :4The structure of a heme, with an iron atom at its center like a jewel, which binds oxygen (O_2)



Figure 5:Hemoglobin

14.4.The Red Blood Cell

The normal red blood cell (RBC) is 8 µm in diameter and has a biconcave shape that maximizes surface area for gas exchange and enhances flexibility. The RBC membrane is stabilized by actin and spectrin, and its outer layer contains mucopolysaccharides involved in blood group antigens. Lacking a nucleus, RBCs cannot synthesize proteins and have an average lifespan of 120 days. Energy for metabolism is derived from the Embden-Meyerhof pathway, which converts glucose to lactate. After RBCs are broken down, globin is recycled into amino acids, and iron is reused for heme production, while protoporphyrin is converted into bilirubin, excreted through bile, and further metabolized by intestinal bacteria.

15. MYELOPOIESIS

Granulocytes, including neutrophils, eosinophils, basophils, and mast cells, play essential roles in immune defense. Neutrophils, the most abundant granulocytes, migrate from the circulation to tissues, where they fight infections through chemotaxis, phagocytosis, and pathogen killing. They ingest bacteria, fungi, or particles, aided by opsonization (coating with antibodies or complement), and destroy them using oxygen-dependent and independent pathways. Oxygen-dependent reactions generate reactive oxygen species, which are toxic to pathogens but can also damage surrounding tissues.

Eosinophils, comprising 1-4% of peripheral blood leukocytes, are involved in allergic reactions, parasitic infections, and tumor defense. They are recognized by their reddish granules. Basophils, which are less frequent (less than 100 cells/µL), have IgE receptors and release histamine and heparin during allergic or anaphylactic responses. Mast cells, derived from CD34+ progenitors, share similarities with basophils, such as having IgE receptors and storing histamine. They migrate to connective tissues, where they participate in allergic and immunological responses. Granulocytes typically survive for a few days in tissues before dying.

15.1. Myelopoiesis and granulocyte development

Under the influence of cytokines like G-CSF, myeloid progenitor cells (CFU-G) differentiate into myeloblasts, promyelocytes, myelocytes, and metamyelocytes, which are recognizable precursor stages of granulocytes. Myeloblasts are large cells with no granules, while promyelocytes develop granules in their cytoplasm. As cell division progresses, myelocytes form secondary granules, and differentiation into



neutrophils, eosinophils, or basophils occurs. Metamyelocytes, which cannot divide, are more mature cells with an indented nucleus and numerous granules. "Juvenile" or "band" forms, with an incomplete nucleus, can be found in peripheral blood, particularly during infections or hematopoietic stress.

1. Neutrophil

Neutrophils are the body's primary defense against bacterial pathogens and are the most abundant type of white blood cell, making up about 50-70% of the total leukocyte count in peripheral blood. These cells are essential for **the** innate immune response and are the first to be recruited to sites of infection or injury. Their primary functions include chemotaxis**,** phagocytosis**,** andpathogen killing**.**

During chemotaxis, neutrophils are directed to the site of infection or inflammation by chemotactic signals such as complement proteins and cytokines released by other immune cells. Upon reaching the site, neutrophils perform phagocytosis, where they engulf and ingest bacterial pathogens. This process is facilitated by opsonization, in which pathogens are coated with molecules like antibodies orcomplement proteins, making them more recognizable and easier for neutrophils to bind and ingest.

Once inside the neutrophil, the bacteria are contained within a phagosome, which then fuses with lysosomes to form a phagolysosome**.** Within this structure, bacteria are killed by several mechanisms, including the production of reactive oxygen species (ROS) such as superoxide and hydrogen peroxide**.** These oxygen-dependent pathways are highly effective at destroying pathogens. Neutrophils also employ oxygen-independent mechanisms**,** such as defensins**,** lysozyme**,** and lactoferrin, to neutralize and kill bacteria.

However, the production of ROS can be a double-edged sword. While these molecules are crucial for pathogen killing, they can also damage surrounding tissues, contributing to inflammationand tissueinjury. This can lead to collateral damage in the host's tissues, a hallmark of conditions like chronic inflammation**,** autoimmune diseases**,** andtissue necrosis**.**

In summary, neutrophils are vital for rapidly controlling bacterial infections. However, their potent antimicrobial activity, if not tightly regulated, can also contribute to the pathogenesis of inflammation and tissue damage. The balance between their effectiveness in pathogen killing and potential for collateral damage underscores their critical role in the innate immune response.



Figure 6 : Neutrophil



2. Eosinophils

Eosinophils account for approximately 1-4% of the total leukocyte population in peripheral blood. These cells are multifunctional and play a key role in allergic reactions, immune responses to parasites, and defense against certain tumors. Eosinophils are particularly important in type 1 hypersensitivity reactions, such as asthma and hay fever, and in the body's defense against parasitic infections, such as those caused by helminths (worms). They are involved in modulating inflammation, often working alongside other immune cells like mast cells and basophils.

Eosinophils are easily identifiable under a microscope due to their reddish-orange granules, which are rich in various proteins, including major basic protein (MBP), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin (EDN). These granules contain toxic molecules that can directly damage the membranes of parasites and contribute to tissue damage during allergic reactions. Additionally, eosinophils secrete cytokines and other mediators that amplify inflammation and recruit other immune cells to the site of infection or injury.

Eosinophils are produced in the bone marrow from precursor cells and can be detected at the myelocyte stage of development, which is an intermediate stage in granulocyte maturation. Upon maturation, eosinophils are released into the bloodstream and migrate to tissues where they are needed. When an allergic or parasitic trigger is detected, eosinophils are attracted to the site throughchemotactic signals, such as eotaxin. Once at the site, they can release their toxic granules, leading to the killing of pathogens or the exacerbation of inflammation.

In the context of parasitic infections, eosinophils play a direct role in attacking the parasites by releasing cytotoxic proteins stored in their granules, which can damage the parasite's outer membranes. This response is particularly crucial in helminth infections, where eosinophils help limit the spread and severity of the infection.

Additionally, eosinophils contribute to tumor defense, although their role is complex and can be both protective and potentially harmful. In some cases, eosinophils can attack tumor cells directly through the release of cytotoxic molecules, while in other instances, they may contribute to the tumor microenvironment, potentially promoting tumor growth and metastasis.

Overall, eosinophils are essential in the body's response to allergens, parasitic infections, and even certain cancers. Their ability to release toxic molecules and cytokines allows them to be powerful effector cells in immune responses, though they also play a role in perpetuating inflammation and tissue damage in allergic diseases.



Figure 7: Eosinophil



3. Basophils

Basophils are one of the least abundant types of white blood cells, making up less than 1% of the total leukocyte count in peripheral blood. Despite their relatively low numbers, basophils play a critical role in the immune system, particularly in the context of allergic and anaphylactic reactions. These cells are equipped with IgE receptors (Immunoglobulin E), which are essential for their activation during allergic responses. When an allergen binds to IgE on the surface of basophils, it triggers the process of degranulation, wherein basophils release a variety of inflammatory mediators such as histamine and heparin.

- Histamine is a potent vasodilator that increases blood vessel permeability, contributing to the symptoms of allergic reactions, such as swelling, redness, and itching.
- Heparin, an anticoagulant, helps prevent blood clotting during inflammatory responses, ensuring that immune cells can efficiently reach affected tissues.

Basophils are involved in both acute and chronic allergic conditions, such as asthma, hay fever, and anaphylaxis. In anaphylaxis, a severe allergic reaction, basophils degranulate rapidly, contributing to the systemic effects of the reaction, including a drop in blood pressure and airway constriction.

In the peripheral blood, basophils are usually found in low numbers, typically fewer than 100 basophils per microliter. Despite their rarity, they are crucial for initiating and amplifying immune responses to allergens and pathogens, particularly through their interactions with other immune cells like mast cells and eosinophils. Their ability to release mediators during degranulation makes them key players in the body's defense against certain pathogens and in modulating immune responses in allergic diseases.



Figure 8: Basophil

16. Mast cells

Mast cells are immune cells that originate from bone marrow CD34+ progenitors and mature in connective tissues, where they play a key role in allergic reactions, immune responses, and tissue repair. They store histamine in their granules and release it upon activation, which contributes to the symptoms of allergic reactions, such as swelling and redness, by dilating blood vessels and increasing permeability. Mast cells have IgE receptors on their surface, and when allergens bind to these receptors, they trigger the release of histamine and other inflammatory mediators. In addition to their role in allergies, mast cells help defend against pathogens, particularly parasites, and contribute to immune responses by releasing cytokines and chemokines that recruit other immune cells. They also play a part in tissue repair by secreting growth factors and enzymes involved in wound healing. However, inappropriate mast cell activation can lead to chronic inflammation and conditions like asthma and mastocytosis, making them important targets for therapeutic interventions.



Figure 9: Mast Cells

17. Monocytes and macrophages

Monocytes are a type of white blood cell that play a pivotal role in the immune system. They are derived from myeloid progenitors (CFU-GM, or Colony-Forming Unit-Granulocyte Monocyte), and their development occurs in the bone marrow through the differentiation of precursor cells. These precursor cells mature into monoblasts and then into promonocytes, which eventually enter the bloodstream as monocytes. Monocytes make up about 2-6% of the total leukocyte count in peripheral blood.

Once in circulation, monocytes are equipped to respond to immune signals and have a critical function in both innate and adaptive immunity. When monocytes encounter inflammatory signals, such as those released during infection or tissue damage, they migrate from the bloodstream into various tissues, where they undergo further differentiation into macrophages. This transformation involves a shift in functional properties: macrophages are larger, more phagocytic, and have enhanced abilities to interact with other immune cells compared to their monocyte precursors.



Figure 10: Monocyte



Macrophages are highly specialized cells involved in phagocytosis, the process by which they engulf and digest pathogens, dead cells, and debris. They are also essential in antigen presentation to T-cells, a key function for the activation of adaptive immunity. Through the presentation of antigen fragments on their surface via major histocompatibility complex (MHC) molecules, macrophages bridge the innate and adaptive immune systems, allowing the body to respond specifically to pathogens.

In addition to their role in pathogen elimination, macrophages secrete a variety of cytokines that are important for immune regulation and tissue repair. For example, TNF-α (Tumor Necrosis Factor-alpha)andIL-1 (Interleukin-1) are pro-inflammatory cytokines that contribute to the inflammatory response by attracting other immune cells to sites of infection or injury. However, the activity of macrophages can be both beneficial and detrimental: while their inflammatory cytokines are essential for pathogen defense and wound healing, excessive or uncontrolled macrophage activity can lead to chronic inflammation, tissue damage, and conditions like autoimmune diseases.

Macrophages are long-lived cells, and they can persist in tissues for extended periods, sometimes even years. This longevity allows them to continually monitor tissue health, clear dead cells, and respond to new infections. Their plasticity allows them to adapt to different tissue environments, where they may adopt various functional states depending on the local signals they receive. These different macrophage states are often classified into two broad categories: M1 macrophages, which are pro-inflammatory and involved in pathogen killing, and M2 macrophages, which are involved in tissue repair and resolving inflammation.



Figure 11: Macrophage

Macrophages also play a vital role in tissue homeostasis and repair. After an infection or injury, they help clear necrotic tissue and produce growth factors that promote tissue regeneration. They also participate in wound healing by secreting factors that help restore tissue structure and function. Given their central roles in both immunity and tissue maintenance, macrophages are indispensable for the body's ability to respond to infections, heal injuries, and maintain overall health.

In summary, monocytes are essential components of the immune system, transitioning from a circulating pool of precursors to specialized macrophages in tissues. Their functions are crucial for pathogen defense, immune regulation, and tissue repair. However, their activity must be tightly regulated to prevent chronic inflammation and damage to healthy tissues.



Figure 12: Monocyte and macrophage



18. Dendritic cells

Dendritic cells are crucial antigen-presenting cells (APCs) found in various tissues throughout the body, including the skin and lymphoid organs such as the lymph nodes and spleen. These cells play an essential role in the immune response by capturing, processing, and presenting antigens to T-cells, which is vital for initiating and regulating immune reactions. Dendritic cells are especially adept at recognizing pathogens, such as bacteria, viruses, and tumor cells, and can efficiently "activate" naive T-cells, a process that helps orchestrate the body's defense against infections or malignancies.

Once dendritic cells capture an antigen, they undergo a process known as maturation. This maturation enables them to migrate to secondary lymphoid organs, where they present the processed antigen to T-cells and thus stimulate specific immune responses. They are especially important for the activation of CD4+ helper T-cellsandCD8+ cytotoxic T-cells, which are involved in the adaptive immune response.

Dendritic cells also play a key role in immunotherapy, particularly in cancer treatment. In this context, dendritic cells can be cultured and expanded in the laboratory, primed with tumor antigens (either from the patient's own cancer cells or from synthetic tumor-related peptides), and then reintroduced into the patient's body. This process enhances the body's immune response to recognize and attack tumor cells, making dendritic cell-based vaccines an important strategy in cancer immunotherapy.

19. Megakaryopoiesis and platelet formation

Platelets are small cell fragments produced by megakaryocytes, large bone marrow cells with a multilobulated nucleus. These megakaryocytes mature under the influence of thrombopoietin(TPO) and produce several thousand platelets each. TPO, along with cytokines like IL-6 and IL-**11**, regulates megakaryocyte development. Platelets are essential for hemostasis (stopping bleeding) and coagulation (blood clotting). The processes of megakaryopoiesis and **thrombopoiesis** are closely related but distinct steps in the formation of platelets.

19.1. Megakaryopoiesis

Definition: Megakaryopoiesis is the process by which megakaryocytes (large bone marrow cells) are formed from hematopoietic stem cells. It is the precursor process leading to platelet

formation.

Process:

- Hematopoietic stem cells differentiate into megakaryoblasts.
- Megakaryoblasts undergo several rounds of endomitosis (a process of DNA replication without cell division), resulting in the development of large, multinucleated megakaryocytes.
- Megakaryocytes mature in the bone marrow under the influence of thrombopoietin(TPO), ahormone that regulates their proliferation and differentiation.
- Megakaryopoiesis primarily occurs in the bone marrow.
- The maturation of megakaryocytes in megakaryopoiesis results in the production of platelet precursor cells, which are the large, multinucleated megakaryocytes themselves.

19.2. Thrombopoiesis

Definition: Thrombopoiesis is the process by which platelets (thrombocytes) are produced frommaturemegakaryocytes.

Process:

- During thrombopoiesis, megakaryocytes extend long cytoplasmic projections called proplatelets into the blood vessels of the bone marrow.
- These proplatelets fragment into small, membrane-bound particles, forming platelets.
- The mature platelets are then released into the bloodstream, where they perform their functions in

19.3.hemostasis and **coagulation**

Platelet formation occurs within the bone marrow, but the platelets themselves are released into the circulation once they are fully formed.

The outcome of thrombopoiesis is the production of platelets, which are essential for blood clotting and wound healing.



Figure13 : Megakaryopoiesis and thrombopoiesis process

20. Lymphatic tissues and immune response

Lymphoid organs are specialized structures of the immune system that play critical roles in the development, activation, and regulation of immune cells, particularly lymphocytes (such as T-cells**,** B-cells, and natural killer cells**)**. These organs are classified into primary and secondary lymphoid organs, each with distinct functions in the immune response.

20.1. Primary lymphoid organs

Primary lymphoid organs are responsible for the maturation and differentiation of lymphocytes. These organs provide the environment necessary for immune cell precursors to become fully functional immune cells.

- **Bone Marrow**: The bone marrow is the primary site for the generation of all blood cells, including **hematopoietic stem cells** that give rise to lymphoid progenitors. It is the site of B-cell maturation and early T-cell development. In adults, it is the most important site of hematopoiesis, continuously producing new blood cells.
- **Thymus**: The thymus is where T-cells mature. Located behind the sternum, it provides an environment for precursor T-cells to differentiate into mature CD4+ helper T-cells and CD8+ cytotoxic T-cells. During this process, T-cells undergo positive and negative selection to ensure they can recognize antigens presented by MHC molecules while avoiding the recognition of self-antigens, which could lead to autoimmunity.

20.2. Secondary lymphoid organs

Secondary lymphoid organs are where mature lymphocytes interact with antigens, undergo **activation**, and initiate an immune response. These organs are distributed throughout the body to provide lymphocytes with access to potential pathogens.

- **Lymph nodes**: Lymph nodes are distributed along the lymphatic vessels and act as filtering stations for lymph, the fluid that circulates throughout tissues. They contain a network **of** B-cells and T-cells that are activated when they encounter pathogens or antigen-presenting cells. Lymph nodes are crucial for coordinating immune responses to infections.

- **Spleen**: The spleen is located in the upper left abdomen and is the largest lymphoid organ in the body. It filters blood, removing old or damaged red blood cells and pathogens. It also provides a site for **B-cells** and **T-cells** to respond to blood-borne pathogens. The spleen is essential for both immune responses and maintaining blood homeostasis.
- **Mucosa-associated lymphoid tissues (MALT)**: MALT includes structures like tonsils**,** Peyer'spatches in the intestines, and the **appendix**. These organs are involved in protecting mucosal surfaces (in the respiratory, gastrointestinal, and urogenital tracts) from pathogens. Peyer's patches in the intestines are particularly important in the immune surveillance of the gut and contribute to the production of IgA antibodies, which protect mucosal surfaces.

20.3.Functionsof lymphoid organs

- **Immune Cell Development**: Primary lymphoid organs like the bone marrow and thymus are crucial for the development and maturation of immune cells, particularly lymphocytes.
- **Immune Cell Activation and Response**: Secondary lymphoid organs provide the sites where mature lymphocytes encounter antigens and are activated to mount an immune response.
- **Filtering and Surveillance**: Lymph nodes and the spleen filter blood and lymph, respectively, trapping pathogens and facilitating their removal by immune cells.
- **Antigen Presentation**: Lymphoid organs are sites where antigen-presenting cells (APCs), such as dendriticcells and macrophages, interact with lymphocytes to trigger adaptive immune responses.

In summary, lymphoid organs play vital roles in immune surveillance, response to infections, and maintaining immune homeostasis. They enable the differentiation, activation, and coordination of immune cells, ensuring that the body is equipped to defend against pathogens while maintaining tolerance to self.

21. B-Lymphocytes

B-cells are responsible for humoral immunity and antibody production. They develop in the bone marrow and are identified by CD19. Upon encountering an antigen, they differentiate into plasma cells (which secrete antibodies) or B-memory cells (which persist in lymph nodes). Their development involves rearranging immunoglobulin genes to produce antigen-specific antibodies.



21.1. T-Lymphocytes

T-cells, a central component of cell-mediated immunity, are essential for recognizing and responding to pathogens, tumor cells, and infected cells. They originate as naive T-cells in the bone marrow and undergo their maturation in the thymus, where they differentiate into two primary subsets: CD4+ (helper) T-cells and CD8+ (cytotoxic) T-cells. These subsets have distinct roles in the immune response, based on their functional properties and the type of antigen they recognize.

1. **CD4+ T-cells (Helper T-cells):**

   CD4+ T-cells play a crucial role in orchestrating the immune response. Their primary function is to activate and coordinate other immune cells, including macrophages, B-cells, and CD8+ T-cells. CD4+ T-cells do this by secreting a variety of cytokines, which are signaling molecules that help regulate the activity of other immune cells. By activating macrophages, CD4+ T-cells enhance phagocytosis and the destruction of pathogens. They also promote B-cells to produce antibodies, thus contributing to humoral immunity. CD4+ T-cells are essential for amplifying and sustaining the immune response, particularly in the context of infections, autoimmune diseases, and even tumor surveillance.

2. **CD8+ T-cells (Cytotoxic T-cells):**CD8+ T-cells are primarily involved in directly eliminating infected or abnormal cells. These cells have a cytotoxic function and are capable of killing infected or tumor cells through the release of cytotoxic molecules such as perforin and granzymes. Perforin creates pores in the target cell's membrane, while granzymes enter the target cell through these pores and induce apoptosis (programmed cell death). CD8+ T-cells are critical for fighting viralinfections and for eliminating cells that have become cancerous or have undergone transformation. Their ability to specifically target and destroy infected cells helps prevent the spread of pathogens within the body.
3. **Antigen recognition via the MHC complex:**

   Both CD4+ and CD8+ T-cells recognize antigens through a highly specific mechanism involving the major histocompatibility complex (MHC). T-cells do not recognize free-floating antigens; instead, they rely on antigens being presented to them on the surface of other cells via MHC molecules.



- **CD4+ T-cells** recognize antigens presented by MHC class II molecules, which are found on antigen-presenting cells (APCs) like dendritic cells, macrophages, and B-cells. These cells present pieces of foreign proteins (antigens) they have ingested and processed, allowing CD4+ T-cells to recognize and initiate the immune response.
- **CD8+ T-cells**, on the other hand, recognize antigens presented by MHC class I molecules, which are expressed on the surface of nearly all nucleated cells in the body. MHC I presents fragments of proteins from within the cell (including those from viruses or mutated proteins), allowing CD8+ T-cells to detect and eliminate cells infected with intracellular pathogens or transformed cells.

The ability of T-cells to differentiate into CD4+ or CD8+ subsets and recognize antigens presented by MHC molecules allows them to have highly specific functions in the immune system, providing a targeted response against pathogens and tumor cells while avoiding damage to healthy tissue. This specificity is crucial for the regulation of immune responses, preventing overreaction or autoimmunity.

Overall, T-cells are indispensable for controlling infections, cancer surveillance, and maintaining the balance of the immune system. Their functions are tightly regulated to ensure that they effectively target harmful cells without causing unnecessary damage to the body's own tissues.

22. Natural killer (NK) cells

Natural Killer (NK) cells are a type of large granular lymphocyte that play a crucial role in innate immunity, providing a rapid response to infected or malignant cells without the need for prior sensitization. Unlike T-cells and B-cells, NK cells do not require antigen presentation through the major histocompatibility complex (MHC) to recognize and kill their targets. This makes NK cells a key component of the body's first line of defense against infections, especially viral infections, andtumor surveillance**.**



Figure14 : NK Cells



22.1.Key features of NK cells:

- **Cytotoxic activity:**

  NK cells are capable of directly killing tumor cells and virally infected cells through a variety of mechanisms. They possess cytotoxic granules containing molecules like perforin and granzymes, which allow them to induce apoptosis (programmed cell death) in their target cells. Perforin creates pores in the target cell membrane, through which granzymes enter and trigger cell death. This makes NK cells important for eliminating abnormal or infected cells without the need for prior exposure to the pathogen or tumor.

- **Innate immune function:**

  Unlike T-cells, which are part of the adaptive immune system and require previous exposure to specific antigens, NK cells are considered part of the innate immune system. They can act immediately upon encountering target cells, providing a rapid immune response in the early stages of infection or tumor development. NK cells are also involved in theclearance of senescent or damaged cells, contributing to tissue homeostasis.

- **Recognition and regulation:**

  NK cells are regulated by a delicate balance of activating **and** inhibitory signals. Their ability to distinguish between healthy cells and abnormal cells is largely controlled by their inhibitory receptors, which recognize MHC class I molecules. Healthy cells express normal levels of MHC I, which binds to inhibitory receptors on NK cells, preventing them from attacking. However, many tumor cells and virus-infected cells downregulate MHC I expression to evade detection by cytotoxic T-cells. NK cells can detect this absence of MHC I and activate their cytotoxic function.

  Additionally, NK cells possess activating receptors that can detect stress signals, abnormal surface proteins, or missing self (the absence of normal MHC I). These signals prompt NK cells to kill the target cells. This ability to detect "missing self" and "altered self" is a key feature of NK cell activity in identifying and destroying cancerous or infected cells.

- **Therapeutic potential:**

  Because NK cells are powerful immune effectors and do not require prior sensitization, they have significant potential for immunotherapy. Researchers are exploring methods to expand NK cells ex vivo (outside the body) and then reintroduce them into patients for the treatment of cancers and viral infections. NK cell-based therapieshave shown promise, particularly in targetinghematologic malignancies such as leukemiaand lymphoma, as well as in enhancing immunity against certain viral infectionslike HIV and hepatitis**.**

22.2.NK cell regulation by mhc molecules:

NK cell function is tightly regulated by the interaction between their inhibitory receptors and MHC class I moleculeson healthy cells. If a target cell has low or absent MHC I expression, NK cells are more likely to recognize it as abnormal and initiate an immune response. This mechanism ensures that NK cells do not attack normal, healthy cells while maintaining the ability to target infected or cancerous cells.

NK cells are an essential component of the innate immune system, offering rapid and broad protection against a wide variety of pathogens and tumors. Their ability to recognize and kill abnormal cells without prior sensitization, combined with their regulation by MHC I molecules, makes them a versatile and efficient arm of the immune response. Furthermore, their expanding role in immunotherapy highlights their therapeutic potential in treating a variety of diseases.



Figure15 : differentiation of hematopoietic stem cells



23. Bone marrow and peripheral blood consequences of consumption and deficient production of Hematopoietic Cells (Erythrocytes, Neutrophils, Platelets)

23.1. Reminder: Key Blood Test parameters and their implications for Rrd blood cell function and anemia diagnosis

The VGM (Volume Globulaire Moyen), CCMH (Concentration Corpusculaire Moyenneen Hémoglobine), Reticulocytes, Hématocrite, and Hémoglobin are key parameters in blood tests that help assess different aspects of red blood cell (RBC) function, count, and the ability to transport oxygen. Here are the details for each of these parameters:

a/ Mean corpuscular volume (MCV)

VGM (or MCV) measures the average volume or size of red blood cells (RBCs), with a normal range typically between 80-100 fL (femtoliters). A low VGM (< 80 fL) indicates microcytic anemia, where RBCs are smaller than normal, commonly seen in iron-deficiency anemia or thalassemia. On the other hand, a high VGM (> 100 fL) points to macrocytic anemia, where RBCs are larger than normal, often associated with vitamin B12 deficiency, folate deficiency, or chronic alcoholism. VGM is an essential parameter for classifying anemias based on the size of RBCs, helping to differentiate between microcytic, normocytic, and macrocytic forms of anemia.

b/ Mean corpuscular hemoglobin concentration (MCHC)

CCMH (or MCHC) measures the average concentration of hemoglobin in a given volume of packed red blood cells (RBCs), reflecting the hemoglobin content relative to the size of the RBC. The normal range for CCMH is typically 32-36 g/dL. A low CCMH (< 32 g/dL) indicates hypochromic anemia, where RBCs have reduced hemoglobin content, often seen in iron-deficiency anemia. On the other hand, a high CCMH (> 36 g/dL) is less common but can occur in conditions like spherocytosis, a hereditary disorder where RBCs are spherical in shape and contain more hemoglobin. CCMH is an important parameter for assessing the degree of RBC hemoglobinization and is particularly useful for diagnosing hypochromic anemias.

c/ Reticulocytes

Reticulocytes are immature red blood cells that still contain residual ribosomal RNA and serve as an indicator of red blood cell production in the bone marrow. Normally comprising about 0.5% to 2% of the total RBC count, an elevated reticulocyte count suggests increased RBC production, commonly seen in response to anemia, such as inacute blood loss or hemolytic anemia. Conversely, a decreased reticulocyte countmay indicate bone marrow dysfunction, as seen in aplasticanemia**,** iron-deficiency anemia, or chronic diseases, where the bone marrow's ability to produce RBCs is impaired. Therefore, reticulocyte counts are crucial for assessing the body's response to anemia, guiding the diagnosis of various hematological conditions, and monitoring treatment efficacy.

d/ Hematocrit (Hct)

Hematocrit (Hct) measures the percentage of blood volume occupied by red blood cells (RBCs), reflecting the concentration of RBCs in the blood. The normal range for hematocrit is 40-50% in men and 36-46% in women. Low hematocrit levels often indicate anemia, which can result from blood loss, nutritional deficiencies, or chronic diseases, reflecting a reduced RBC proportion in the blood. High hematocrit levels may suggest polycythemia, a condition where there is excessive RBC production, often due to chronic hypoxia or disorders like polycythemia vera. In some cases, high hematocrit could also indicate dehydration, where the volume of plasma decreases, raising the relative concentration of RBCs. Hematocrit levels are essential for diagnosing anemia, polycythemia, and dehydration.

e/ Hémoglobine (hemoglobin, Hb)

Hemoglobin levels are a crucial indicator of the blood's ability to carry oxygen, with normal ranges typically being 13-17 g/dL for men and 12-16 g/dL for women. Low hemoglobin levels often signal anemia, which can result from causes such as iron deficiency, chronic diseases, or blood loss, leading to a reduced oxygen-carrying capacity of the blood. On the other hand, high hemoglobin levels may indicate conditions like polycythemia or chronic lung diseases, where the body compensates for insufficient oxygen levels by producing more red blood cells (RBCs). Monitoring hemoglobin levels is essential for diagnosing anemia and assessing overall oxygen delivery capacity, with both low and high levels pointing to potential underlying health issues such as anemia or polycythemia.

f/ Summary of parameters:

- **VGM (MCV)**: Measures RBC size. Low levels indicate microcytic anemia, while high levels indicate macrocytic anemia.
- **CCMH (MCHC)**: Measures hemoglobin concentration within RBCs. Low levels suggest hypochromic anemia, while high levels can indicate spherocytosis or dehydration.
- **Reticulocytes**: Immature RBCs. Elevated levels indicate active RBC production (in response to anemia), while low levels suggest bone marrow issues.
- **Hématocrite (Hct)**: Percentage of RBCs in blood. Low levels indicate anemia, while high levels can indicate polycythemia or dehydration.
- **Hémoglobine (Hb)**: Reflects oxygen-carrying capacity. Low levels suggest anemia, while high levels may indicate polycythemia or chronic lung disease.

23.2.**Consequences of the consumption of hematopoietic cells**

Defects in the production of hematopoietic cells are often associated with bone marrow disorders such as aplastic anemia, myelodysplastic syndromes (MDS), or leukemias. These deficiencies can have several causes: genetic, toxic (medications, radiation), or infectious.

- **Bone marrow**:
    - Insufficient production of blood cells by the bone marrow may result from direct damage to the bone marrow or dysfunction of hematopoietic stem cells. This can lead to bone marrow hypoplasia, where blood cell production is reduced.
    - **Myelodysplastic syndromes (MDS)** and aplastic anemia are examples of conditions where the production of blood cells is severely impaired.
- **Peripheral blood**:
    - **Anemia**: A defect in the production of erythrocytes can lead to hypoproliferative anemia, characterized by low erythrocyte and hemoglobin levels. This can be caused by a depletion of erythrocyte precursors in the bone marrow or an insufficient response to erythropoietin.



- **Neutropenia**: A defect in the production of neutrophils by the bone marrow leads to neutropenia, increasing susceptibility to infections.
- **Thrombocytopenia**: If platelet production is impaired (as in myelodysplastic syndromes or aplastic anemia), thrombocytopenia can occur, increasing the risk of bleeding and bruising.

23.3.Clinical examples

- **Iron-deficiency anemia**: This does not directly involve a production defect in the bone marrow but rather an inability to produce functional erythrocytes due to a lack of iron, which is essential for hemoglobin production.
- **Acute leukemias**: These involve the production of abnormal blood cells that cannot function properly, leading to bone marrow failure. The bone marrow produces large amounts of leukemia cells, but these cells are non-functional.

23.4.Different types of anemia and their details

Anemia is a condition in which the number of red blood cells (RBCs) or the amount of hemoglobin in the blood is lower than normal, reducing the ability of blood to carry oxygen to tissues. There are several types of anemia, each with distinct causes, symptoms, and treatments.

1. Iron-deficiency anemia

Iron deficiency anemia occurs when there is an insufficient amount of iron in the body, which is essential for producing hemoglobin in red blood cells. This can result from a poor diet, chronic blood loss (such as heavy menstrual periods or gastrointestinal bleeding), or conditions that affect the body's ability to absorb iron properly, like celiac disease. Symptoms include fatigue, pale skin, weakness, shortness of breath, dizziness, and unusual cravings for non-nutritive substances like ice or dirt, a condition known as pica. Treatment involves iron supplements, dietary changes to include iron-rich foods such as red meat, leafy greens, and legumes, as well as addressing any underlying causes of blood loss to restore iron levels and improve overall health.



2. Vitamin B12 deficiency anemia (pernicious anemia)

Vitamin B12 deficiency anemia occurs when there is an insufficient amount of vitamin B12, which is essential for the production of red blood cells. This deficiency can result from a poor diet, gastrointestinal disorders such as Crohn's disease, or an inability to absorb vitamin B12 due to a lack of intrinsic factor, a protein necessary for B12 absorption, which is common in pernicious anemia. Symptoms include fatigue, weakness, pallor, glossitis (inflamed tongue), and neurological signs such as numbness or tingling in the hands and feet, difficulty walking, and memory problems. Treatment typically involves vitamin B12 injections or high-dose oral supplements, as well as addressing any underlying conditions that impair vitamin B12 absorption, to restore normal red blood cell production and prevent long-term neurological damage.

3. Folate deficiency anemia

Folate deficiency anemia occurs when there is an insufficient amount of folate (vitamin B9) in the body, which is essential for red blood cell production. This deficiency can result from poor diet, alcoholism, certain medications, or conditions that affect nutrient absorption, such as celiac disease or inflammatory bowel disease. Symptoms of folate deficiency anemia are similar to those of vitamin B12 deficiency anemia and include fatigue, weakness, pallor, as well as mouth sores and a swollen, red tongue. Treatment typically involves folate supplementation and dietary changes to include folate-rich foods, such as leafy greens, fruits, beans, and fortified cereals, to help replenish the body's folate stores and support proper red blood cell production.

4. Anemia of chronic disease (ACD)

Anemia of chronic disease (ACD) is often associated with long-term conditions such as infections, inflammatory diseases (like rheumatoid arthritis), kidney disease, or cancer. Chronic inflammation interferes with the production of red blood cells and disrupts the body's ability to utilize iron effectively. Symptoms of ACD are similar to other types of anemia, including fatigue, weakness, and pallor, but these symptoms may be mild and develop gradually due to the underlying chronic condition. Treatment primarily involves managing the underlying disease, which can help alleviate the anemia. In some cases, erythropoiesis-stimulating agents (ESAs) or iron supplements may be prescribed to stimulate red blood cell

production and improve iron utilization. Addressing the root cause is essential for effective management of both the anemia and the underlying condition.

5. Hemolytic anemia

Hemolytic anemia occurs when red blood cells are destroyed prematurely in the bloodstream, leading to a shortage of RBCs. This condition can be caused by various factors, including autoimmune diseases (such as autoimmune hemolytic anemia), inherited disorders (like sickle cell disease or thalassemia), infections, certain medications, or exposure to toxins. Symptoms often include fatigue, pallor, jaundice (yellowing of the skin and eyes), dark urine, and an enlarged spleen (splenomegaly). Treatment depends on the underlying cause and may involve immunosuppressive therapy for autoimmune-related hemolysis, blood transfusions to replace destroyed RBCs, or management of other conditions like sickle cell disease. Early diagnosis and appropriate treatment are critical for preventing complications and improving the patient's quality of life.

6. Sickle cell anemia

Sickle cell anemia is a genetic disorder in which the hemoglobin in red blood cells is abnormal, specifically hemoglobin S. This causes the RBCs to become sickle-shaped, which makes them less flexible and more prone to blocking blood flow. These sickle-shaped cells also have a shorter lifespan, leading to chronic anemia. Symptoms of sickle cell anemia include pain episodes (known as sickle cell crises), fatigue, frequent infections, delayed growth, and complications such as stroke or organ damage due to impaired blood flow. Treatment focuses on managing pain, preventing infections, and improving blood flow, with options including pain management, blood transfusions, hydroxyurea (a medication to reduce the frequency of pain crises), and bone marrow or stem cell transplants in severe cases. Early intervention and comprehensive care are essential to managing the disease and improving the quality of life for affected individuals.

7. Thalassemia

Thalassemia is an inherited blood disorder characterized by the production of abnormal forms of hemoglobin, leading to the destruction of red blood cells and resulting in anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, depending on which part of the hemoglobin molecule is affected. Symptoms typically include fatigue, weakness, paleness, jaundice, and in children,

growth retardation. Severe cases of thalassemia can lead to bone deformities and organ damage due to iron overload, a consequence of frequent blood transfusions. Treatment involves regular blood transfusions to maintain adequate hemoglobin levels, iron chelation therapy to remove excess iron from the body, and in severe cases, bone marrow or stem cell transplants to correct the underlying hematological issue. Early diagnosis and management are crucial to preventing complications and improving the patient's quality of life.

8. Aplastic anemia

Aplastic anemia is a condition where the bone marrow fails to produce an adequate number of blood cells, leading to a shortage of red blood cells, white blood cells, and platelets. The causes of aplastic anemia can include autoimmune diseases, exposure to certain chemicals or medications, viral infections, or it may occur without a known cause (idiopathic). Symptoms include fatigue, weakness, shortness of breath, increased susceptibility to infections, and easy bruising or bleeding. Treatment options vary depending on the severity and underlying cause, and can include blood transfusions, bone marrow or stem cell transplants, immunosuppressive therapy, and medications such as eltrombopag to stimulate blood cell production. Prompt and effective treatment is critical to managing the disease and improving the patient's quality of life

9. Megaloblastic anemia

Megaloblastic anemia is a type of anemia caused by the production of abnormally large and immature red blood cells, called megaloblasts, typically due to a deficiency in vitamin B12 or folate. Symptoms include fatigue, weakness, pale skin, glossitis (inflammation of the tongue), and, in severe cases, neurological symptoms similar to those seen in vitamin B12 deficiency anemia, such as numbness or tingling in the hands and feet. Treatment involves supplementing the deficient vitamin, either vitamin B12 or folate, depending on the underlying cause of the deficiency, to help correct the anemia and prevent further complications.

10. Polycythemia vera (PV)

Polycythemia vera is a rare condition where the bone marrow produces an excessive number of red blood cells, leading to thickened blood. This condition is often caused by a mutation in the JAK2 gene. Common symptoms include headache, dizziness, itching (particularly after a warm shower), an increased risk of

blood clots, and an enlarged spleen. Treatment typically involves phlebotomy (removal of blood) to reduce blood thickness, medications to manage blood viscosity, and, in some cases, chemotherapy or radiation therapy to decrease the production of red blood cells. Proper management is essential to prevent complications such as stroke or heart attack due to increased blood viscosity.

23.4.Treatment of anemia

The treatment of anemia depends on its underlying cause, severity, and the specific type of anemia. Here's an overview of the common approaches for treating different forms of anemia:

1. Iron-Deficiency Anemia

- **Treatment**:
  - **Oral iron supplements**: The first-line treatment for iron-deficiency anemia is iron supplementation (e.g., ferrous sulfate), which helps replenish iron stores in the body.
  - **Intravenous iron**: In cases where oral iron is poorly tolerated or ineffective (e.g., in severe anemia or malabsorption), intravenous iron (e.g., iron sucrose, ferric carboxymaltose) may be administered.
  - **Dietary changes**: Increasing dietary intake of iron-rich foods (e.g., red meat, poultry, fish, beans, and fortified cereals) may help in mild cases.

2. **Vitamin B12 deficiency anemia (Pernicious anemia)**

- **Treatment**:
  - **Vitamin B12 injections**: In cases of pernicious anemia or when absorption is impaired, vitamin B12 injections are often required. These are typically given intramuscularly (IM) every few weeks or as a high-dose oral supplement.
  - **Oral vitamin B12**: For less severe deficiency or when absorption is adequate, oral B12 supplements may be sufficient.
  - **Dietary adjustments**: For individuals with dietary B12 deficiency (e.g., vegans), B12-rich foods (meat, eggs, dairy) or fortified plant-based foods should be included in the diet.

3. Folate-Deficiency Anemia

- **Treatment**:

  - **Folic Acid Supplements**: Folic acid (vitamin B9) supplementation is the primary treatment. It can be given orally or in some cases via injection if the patient has severe deficiency.
  - **Dietary Adjustments**: Increasing the intake of folate-rich foods (e.g., leafy greens, citrus fruits, beans, and fortified cereals) can help in mild cases.

4. **Aplastic anemia**

- **Treatment**:

  - **Bone marrow stimulants**: Drugs like erythropoietin or granulocyte colony-stimulating factor (G-CSF) may be used to stimulate the bone marrow's production of blood cells.
  - **Immunosuppressive Therapy**: Medications such as antithymocyte globulin (ATG) or **cyclosporine** are used to suppress the immune system if it's attacking the bone marrow.
  - **Bone marrow transplant**: For severe cases, especially in younger patients, a bone marrow transplant (also called a stem cell transplant) may be the definitive treatment.
  - **Blood transfusions**: Patients with aplastic anemia may require regular transfusions of red blood cells and platelets to manage severe anemia and low platelet counts.

5. **Hemolytic anemia**

- **Treatment**:

  - **Corticosteroids**: In some autoimmune types of hemolytic anemia, corticosteroids (e.g., prednisone) may be used to suppress the immune system and reduce the destruction of red blood cells.
  - **Immunosuppressive therapy**: If steroids are not effective, additional immunosuppressive drugs (e.g., azathioprine, rituximab) may be used.
  - **Blood transfusions**: In cases of severe hemolysis, blood transfusions may be needed to replace the destroyed red blood cells.



- **Splenectomy**: In cases where the spleen is causing excessive destruction of red blood cells, removal of the spleen may be considered (splenectomy).
- **Treatment of underlying causes**: If hemolytic anemia is due to an underlying condition, such as an infection or autoimmune disease, that condition must also be treated.

6. **Sickle cell anemia**

- **Treatment**:

  - **Pain management**: Acute episodes of pain (sickle cell crisis) are managed with pain relief (e.g., acetaminophen, opioids, NSAIDs).
  - **Hydroxyurea**: This drug can increase the production of fetal hemoglobin, which helps reduce the frequency of pain crises and complications.
  - **Blood transfusions**: In cases of severe anemia or sickle cell crises, blood transfusions may be required.
  - **Bone marrow/stem cell transplant**: The only potential cure for sickle cell anemia is a stem cell transplant (bone marrow transplant), although it is not suitable for all patients.
  - **Gene therapy**: Research into gene therapy is ongoing and may become a future treatment option.

7. **Thalassemia**

- **Treatment**:

  - **Blood transfusions**: Regular transfusions are often necessary to maintain red blood cell counts in people with severe thalassemia.
  - **Iron chelation therapy**: Chronic blood transfusions can lead to iron overload, so iron-chelating agents (e.g., deferasirox, deferoxamine) are used to prevent damage to organs caused by excess iron.
  - **Bone marrow transplant**: In some cases, bone marrow transplantation may offer a potential cure for thalassemia.
  - **Gene therapy**: Like sickle cell anemia, gene therapy is being researched as a potential future treatment.

8. **Chronic kidney disease-related anemia**

- **Treatment**:

  - **Erythropoiesis-stimulating agents (ESAs)**: Medications such as epoetin alfa or **darbepoetin alfa** are used to stimulate the bone marrow to produce red blood cells.
  - **Iron supplements**: Both oral and intravenous iron may be used to treat iron deficiency and support erythropoiesis.
  - **Dialysis**: For patients undergoing dialysis, anemia is often treated with a combination of ESAs and iron supplementation.

23.5.General management

In severe cases of anemia, blood transfusions may be required to rapidly increase the number of red blood cells and enhance oxygen delivery to tissues, providing immediate relief to the patient. Alongside transfusions, regular monitoring of hemoglobin, iron levels, and other blood parameters is crucial to assess the effectiveness of treatment and prevent complications. This monitoring is especially important for patients undergoing long-term therapies, as it helps to adjust treatment plans, manage side effects, and ensure that the underlying cause of anemia is effectively addressed. By closely tracking these blood parameters, healthcare providers can optimize patient care and minimize the risks associated with anemia management.

24.Thrombocytopenia and pregnancy

The occurrence of thrombocytopenia in a pregnant woman is a common phenomenon. It is most often idiopathic gestational thrombocytopenia, which poses no risk to either the mother or the baby and does not require any special precautions during delivery. This type of thrombocytopenia is usually moderate (greater than 70 x 10^9/L) and is not associated with any hemorrhagic syndrome. The diagnosis is based on the following criteria:

- Absence of other causes of thrombocytopenia (such as medications).
- Absence of platelet-specific antibodies.
- Absence of signs of hemolytic uremic syndrome (HUS) or HELLP syndrome (normal blood pressure, renal function, liver tests, and uric acid levels).
- Normal platelet count before and after pregnancy.

25.Importance of blood smear and its technique: preparation and MGG staining

A blood smearis a valuable diagnostic tool that allows the examination of the morphology of blood cells under a microscope. It is an essential method in hematology, particularly for identifying various blood disorders, infections, and abnormalities in blood cell structure. The blood smear provides insight into the size, shape, and number of blood cells, enabling the diagnosis of conditions such as anemia, leukemia, and malaria. It also helps in detecting parasitic infections, such as Plasmodium (the causative agent of malaria), by identifying the parasites within the red blood cells.

25.1.Preparation of blood smear

The preparation of a blood smear involves several key steps to ensure a good-quality sample for microscopic analysis:

1. **Collection of blood sample:**
    - A drop of blood is obtained, typically from a fingertip or ear lobe (for adults) or from a heel (for infants). The blood should be fresh to avoid any cellular degradation.
    - Blood is collected into a small glass tube or directly onto a microscope slide.
2. **Placing the blood on the slide:**
    - A small drop of blood (usually about 2–3 mm in diameter) is placed near one edge of a clean glass microscope slide. The drop should be neither too large nor too small to ensure a good spread.
3. **Spreading the blood:**
    - Using another slide (called the spreader slide), the drop is spread evenly over the surface of the microscope slide. The spreader slide is placed at a 30-45 degree angle to the slide with the drop of blood.
    - The blood drop is gently pushed across the slide by the spreader slide to create a thin, even smear. The goal is to create a monolayer of cells with a smooth transition from dense to sparse blood.



4. **Drying the smear:**

   - After spreading the blood, the smear is left to air dry. The smear should not be subjected to heat or rapid drying to avoid distorting the blood cells.

5. **Fixation (Optional):**

   - In some cases, the smear may be fixed with methanol or other fixatives to preserve the blood cells. This step helps in enhancing the quality of staining, especially when a long-term slide preparation is needed.

25.2. Staining the blood smear: MGG (May-Grünwald Giemsa) Staining

The **May-Grünwald Giemsa (MGG)** stain is one of the most commonly used stains for blood smears, especially in the diagnosis of hematological disorders and parasitic infections. The MGG stain is a combination of two stains: May-Grünwald and Giemsa, which together help in distinguishing different blood cell types and detecting abnormal cells. The technique involves a series of steps to apply and develop the stain:

1. **May-Grünwald staining:**

   - The smear is first covered with May-Grünwald solution (a mixture of methanol, eosin, and other reagents) for about 3–5 minutes. The stain begins the process of binding to the cellular components, particularly the proteins in the cytoplasm and the nuclear material of the cells.
   - May-Grünwald helps in providing the initial coloration to the cells, with red to pink staining of cytoplasm and a pale blue coloration of the nuclei.

2. **Washing and giemsa staining:**

   - After the initial staining, the smear is rinsed gently with water to remove excess stain.
   - The slide is then flooded with giemsa stain, which is typically diluted with phosphate buffer (pH 7.2–7.4). The Giemsa stain provides more detailed and specific coloration to the blood cells.

- The smear is left in the Giemsa solution for 10–15 minutes to allow the stain to penetrate the cells. Giemsa stain enhances the contrast between the different cell types, allowing for the identification of subtle differences in cell morphology.

3. **Rinsing and drying:**

- After staining, the slide is rinsed again with phosphate buffer or distilled water to remove excess stain. The smear is then air-dried completely, ensuring that no moisture remains before viewing under the microscope.

4. **Interpretation of the Stained Blood Smear**

Under the microscope, the MGG-stained blood smear will provide clear differentiation between the various types of blood cells:

- **Red blood cells (RBCs)**: They will appear as round, biconcave discs, typically pink to pale, with no nucleus.
- **White blood cells (WBCs)**: These cells have a large, irregular-shaped nucleus, and their cytoplasm can range from pale blue (in lymphocytes) to a more granular appearance (in granulocytes such as neutrophils, eosinophils, and basophils).
- **Platelets**: Small, round or oval cell fragments with a bluish tint can be seen in the smear.
- **Parasites (*Plasmodium spp.)*:** Malaria parasites, for example, can be identified by their characteristic stages (trophozoites, schizonts, gametocytes) within the red blood cells. The MGG stain highlights the parasite's cytoplasm and chromatin.

25.3. Advantages of MGG Staining

- **Differentiation of blood cell types**: The MGG stain provides excellent differentiation of the various blood cell types, including different forms of white blood cells, allowing for the identification of abnormal or immature cells.
- **Parasite Detection**: It is particularly useful in identifying parasites, such as Plasmodium in malaria or Leishmania in leishmaniasis, within the blood.
- **Simple and cost-effective**: The technique is relatively straightforward and inexpensive compared to more advanced staining methods or molecular tests.



- **Routine use**: The MGG stain is routinely used in hematology labs for blood smears, making it a reliable and widely available technique.

Blood smears are essential for the evaluation of blood cell morphology and the identification of various blood disorders and infections. The preparation and staining techniques, particularly the May-Grünwald Giemsa (MGG)stain, provide crucial information about the nature of the cells and any abnormalities or infections present in the blood. This method is indispensable for both diagnostic and research purposes, helping clinicians and researchers to identify conditions such as anemia, leukemia, and parasitic infections, thereby guiding appropriate treatment and management strategies.

26.Blood Transfusion

26.1. Labile blood products (LBP)

Labile blood products are derived from the fractionation of whole blood donations or from apheresis collections using cell separators. These products are crucial for various medical conditions, such as anemia, bleeding disorders, and hematologic diseases. They are called "labile" because they have a limited shelf life and must be used within a short period after collection. The main types of labile blood products include:

1. **Red blood cell concentrates (RBCs)**

   Red blood cell concentrates are prepared from whole blood donations by separating the red blood cells from the plasma and other components. RBCs are primarily used for anemia treatment, particularly in cases where the body is unable to produce sufficient red blood cells or in patients who have lost a significant amount of blood (e.g., after surgery or trauma). They are also used in hemoglobinopathies (like sickle cell anemia) and other disorders that affect red blood cell production. The concentrates can be stored for several weeks under controlled conditions.

2. **Standard platelet concentrates (PCs)**

Platelet concentrates are obtained by separating platelets from whole blood donations. Platelets are essential for blood clotting, and platelet concentrates are used to treat patients with thrombocytopenia(low platelet count) due to various causes, such as leukemia, chemotherapy, or bone

marrow disorders. These concentrates can be derived from multiple donations or from a single donor through a process known as apheresis (described below).

3. **Apheresis platelet concentrates (APCs)**

   Apheresis platelets are specifically collected through a process called **apheresis**, in which only the platelets are harvested from a donor's blood, and the remaining components (plasma, red blood cells, etc.) are returned to the donor. This method allows for the collection of larger quantities of platelets from a single donor, which can be especially beneficial for patients who need a higher platelet count or have specific platelet disorders. Apheresis platelets are particularly used for patients who require long-term or large-volume platelet support, such as those undergoing bone marrow transplants or patients with severe bleeding disorders.

4. **Apheresis granulocyte concentrates**

   Granulocytes are a type of white blood cell essential for fighting infections, particularly bacterial and fungal infections. Granulocyte concentrates can be collected through apheresis, where the donor's granulocytes are separated and collected while the rest of their blood is returned. This product is often used for patients with severe neutropenia (low neutrophil count) or those who are unable to mount an effective immune response due to conditions like bone marrow failureorchemotherapy-induced immunosuppression. Granulocyte transfusions help boost the patient's immune system and aid in fighting infections.

5. **Fresh frozen plasma (FFP)**

   Plasma is the liquid portion of blood that contains water, electrolytes, proteins, hormones, and waste products. Fresh frozen plasma is collected from whole blood donations, and it is frozen immediately after collection to preserve clotting factors, which are crucial for blood coagulation. FFP is primarily used to treat patients with coagulopathies (disorders of blood clotting), such as those caused by liver disease, vitamin Kdeficiency, or bleeding disorders like hemophilia. It is also used in patients undergoing surgery or trauma when blood clotting needs to be restored quickly.



6. **H**ematopoietic Stem Cell Concentrates **(HSCs)**

   Hematopoietic stem cells are the precursor cells in the bone marrow that give rise to all blood cells. These cells can be collected from either bone marrow or peripheral blood (after mobilization with growth factors). Hematopoietic stem cell concentrates are used primarily for bone marrow transplants in patients with hematologic diseases like leukemia,lymphoma, or myelodysplastic syndromes. The stem cells are transplanted into the patient's bone marrow to regenerate normal blood cell production. This type of therapy can be autologous (from the patient themselves) or allogeneic (from a donor).

26.2.Development of labile blood products

Labile blood products play an integral role in treating various hematologic conditions, managing blood loss, and supporting patients with immune deficiencies. Advances in blood collection, fractionation, and apheresis technologies have improved the quality and availability of these products, making them essential components of modern medical care.

- **Apheresis** allows for the collection of specific blood components, enabling better matching of transfusion needs and reducing the risk of contamination from unwanted components. This method not only improves the quality of the transfused blood but also maximizes donor safety by minimizing the loss of other blood components that are not needed.
- **Blood product storage and handling** have also evolved. For example, red blood cell concentrates are now typically stored in a refrigerated state and have a shelf life of up to 42 days, depending on the additive solution used. Platelets, however, must be stored at room temperature and have a much shorter shelf life of around 5 days, which highlights the importance of timely use.
- **Hematopoietic stem cell transplantation** has revolutionized the treatment of hematologic cancers and bone marrow disorders. This therapy allows for the reconstitution of the patient’s hematopoietic system and can offer a potential cure for conditions that were previously fatal.



26.3.Biological screening of blood donations

Each blood donation undergoes a series of tests to ensure both immunohematological compatibility and the safety of the product for transfusion. These screenings are essential for minimizing the risk of transmission of infectious diseases and ensuring the health of the recipients. The following tests are performed on each blood donation:

1. **Immunohematological compatibility tests**

   These tests are performed to confirm that the blood is compatible with the recipient's blood type, reducing the risk of hemolytic transfusion reactions.

2. **Systematic screening for infectious diseases**

   The following infectious agents are tested for in every blood donation:

   - Syphilis: Testing for the Treponema pallidum bacterium, which causes syphilis, helps ensure that no infected blood is transfused.
   - Hepatitis B: Screening for the HBs antigen, which indicates the presence of the hepatitis Bvirus (HBV)**,** and the anti-HBc antibodies, which may suggest prior exposure to HBV.
   - Hepatitis C**:** Testing for anti-HCV antibodies, which indicates exposure to the hepatitis Cvirus (HCV)**.**
   - HIV: Screening for anti-HIV 1 and 2 antibodies, which indicates potential exposure to the human immunodeficiency virus (HIV**)**, the virus responsible for AIDS.
   - HTLV: Testing for anti-HTLV 1 and 2 antibodies**,** which indicates exposure to the Human T-cell Leukemia Virus (HTLV)**,** which is associated with certain types of leukemia.

3. **Alanine aminotransferase (ALAT) testing**

   The dosage of alanine aminotransferases (ALAT) is used as a screening test for liver damage. Elevated levels of ALAT may indicate liver infection or inflammation, potentially due to viral infections such as hepatitis. This test helps identify seronegative donors who may still carry a viral infection, reducing the risk of transmission.If anti-HBcantibodies or an elevated ALAT level is



detected, the donation is discarded, as these markers suggest that the donor may pose a higher risk of transmitting viral diseases, even though they are seronegative for certain infections.

4. **Malaria antibody screening**

   Blood donors who have recently stayed in endemic malaria regions are tested for anti-malariaantibodies. This ensures that blood from donors who may have been exposed to Plasmodiumparasites (the cause of malaria) is not transfused, preventing the potential transmission of the disease.

5. **Cytomegalovirus (CMV) serologycytomegalovirus (CMV)** is a common virus that can cause severe infections in immunocompromised individuals, such as transplant patients or patients with HIV/AIDS. To minimize the risk of CMV transmission, CMVserology is performed. CMV-negative blood products are selected for transfusion to vulnerable patients, ensuring that the risk of infection is minimized.

27.Processof blood donation screening and donation disposal

If any of these tests yield positive results, the blood donation is immediately discarded to avoid the risk of transmitting any viral or bacterial infections. The donor is then informed of the results, and depending on the situation, further investigations or treatment may be recommended. In cases of positive HIV,hepatitis, or HTLV tests, the donor may be deferred from future donations to protect both their health and that of the recipients.

27.1.Fractionation

Whole blood undergoes a series of centrifugations and extractions, resulting in the production of ared blood cell concentrate (RBC)**,** a standard platelet concentrate (SPC), and a unit of plasma for each donation. Platelet concentrates (PCs) and plasmas can also be collected by cytapheresisor plasmapheresis, respectively. The plasma sent to the LFFB (French Blood Transfusion Establishment) is intended for the production of blood-derived medicinal products**.**

27.2.Ethical aspects related to blood donor rights in algeria

Blood donation is a critical component of modern healthcare systems, saving countless lives each year. However, it is also accompanied by various ethical considerations that must be respected to ensure the well-being of donors and the integrity of the donation process. In Algeria, the ethical guidelines governing blood donation are designed to uphold the rights and dignity of donors, while ensuring that blood products are safely collected and used. The following are key ethical aspects related to the rights of blood donors in Algeria:

1. **Pre-donation medical interview and consent**

- Before any blood donation, the donor must undergo amedical interview to assess their eligibility and ensure that they do not have any underlying conditions that would make donating unsafe for them or the recipient. This interview is conducted inaccordancewithmedicalstandards and aims to protect the health of the donor.
- Informed consent is a fundamental principle in medical ethics. Donors must be fully informed about the donationprocess, its potential risks, and any post-donation care that may be required. This information should be provided before and during the blood collection process, ensuring that donors have a clear understanding of what is involved and can make an informed decision about whether or not to proceed.
- The righttoautonomy ensures that the donor has the freedom to decide whether or not to donate blood without any form of coercion or pressure. This is an essential aspect ofethicalblooddonationpractices and must be respected at all times.

2. **Age requirements and eligibility**

- In Algeria, the minimum age for blood donation is 18 years**,** ensuring that donors are legally considered adults and are capable of providing informed consent. Additionally, the maximum age limit for blood donation is 65 years**,** which helps ensure the donor's health and safety, as older individuals may be at a higher risk for adverse reactions.
- However, exceptions can be made in cases where blood is required fortherapeuticordiagnosticpurposes, regardless of the donor's age. This allows for the possibility of medical exceptions in cases such asemergency transfusionsor when a specific medical need arises.

Nevertheless, even in these situations, the donor's health must be prioritized and their eligibility assessed on a case-by-case basis.

- These age requirements reflect the balance between maximizing the availability of blood donationswhile also safeguarding the well-being of the donor. Age limits help to ensure that the body of the donor is in optimal condition to give blood without undue risk.

3. **Confidentiality and Privacy**

- Donor confidentiality is an essential ethical principle in Algeria's blood donation practices. Personal and medical information provided during the pre-donation medical interview must be kept confidential and handled in accordance with privacylaws. Donors should be assured that their information will not be shared without their consent, and their identity will remain private during thescreeningprocess.
- The ethical obligation of confidentiality extends beyond the donation process itself and ensures that donors' personal health information is protected at all stages, from the interview to the final use of the blood.

4. **Voluntary and non-paid donations**

- In Algeria, as in many countries around the world, blood donation is strictly voluntary. Donors should never be paid for their donation. The ethical principle ofaltruism is at the core of blood donation, as it ensures that individuals give blood for humanitarian reasons and not for personal financial gain.
- Paid blood donations can lead to ethical concerns, including the risk of exploitation, coercion, and the potential for donors to misrepresent their health status in exchange for compensation. Voluntary donations maintain the integrity of the process and ensure that the blood collected is from individuals who genuinely wish to help others.

5. **Post-donation care and safety**

- After blood donation, the well-being of the donor must continue to be a priority. Ethical guidelines require that post-donation care be provided to ensure that donors do not experience adverse health effects after the donation. Donors should be monitored for any immediate reactions, and appropriate medical assistance should be available if needed.

- Post-donation adviceshould include recommendations for hydration**,** rest, and nutrition, as well as instructions on what to do if any complications arise after the donation. Donors should also be informed of the potential side effects of blood donation, such as dizziness or fatigue, and instructed on how to manage these symptoms if they occur.

6. **Non-discrimination and equal access**

- Blood donation practices in Algeria must ensure that no individual is discriminated against on the basis of their race, gender, sexual orientation, religion, or socio-economic status. Blood donation should be an inclusive practice that encourages individuals from all walks of life to contribute.
- While blood donation policies may set eligibility requirements (such as age and health status), these policies should be fair**,** equitable, and non-discriminatory**.** Any exclusion criteria, such as restrictions on men who have sex with men (MSM), should be based on scientific evidenceandpublic health guidance, not on unfounded biases or stigmas.

7. **T**ransparency and Education

- Ethical blood donation requires that donors are given transparent information about how their blood will be used, the risks involved in the donation, and the benefits of donating**.** Public education campaigns can help increase awareness of the importance of blood donation and the role it plays in saving lives.
- It is also critical to ensure that the donationprocess is fully transparent, with clear guidelines and regulations for both donors and medical staff. Donors should be aware of how their blood will be processed, stored, and used for the benefit of others. Ethical practices in blood collection also include being upfront about any financial **costs** associated with the collection and distribution process (such as testing or processing fees) if applicable.

27.2.Maincontraindications for blood donation in france

- Age: Over 65 years for whole blood donation, over 60 years for platelet and plasma apheresis donations, and over 50 years for granulocyte donations.
- Weight: Less than 48 kg.
- Hemoglobin level: Below 11 g/dL.
- Unstable cardiovascular disease.

- Recent medication use that may harm the recipient.
- History of autoimmune diseases or cancer.
- Vaccination received less than 10 days ago.
- Recent infection.
- Dental surgery performed less than 1 month ago.
- History of corneal or dura mater transplant or a family history of neurodegenerative diseases (to prevent the transmission of Creutzfeldt-Jakob disease).
- Visceral surgery or endoscopic examination performed less than 6 months ago, or a history of blood transfusion (due to the risk of hepatitis C virus transmission).
- History of intravenous drug use or high-risk sexual practices, or having had sexual relations with a new partner within the past 6 months.

28.Hematology transplants

Hematopoietic stem cell transplantation holds a special place among organ and tissue transplants, characterized by the following features: the transplanted organ is renewable; stem cells are introduced at a site distant from their usual location and will naturally colonize the bone, which is initially devoid of them, due to the conditioning of the transplant. This allows them to proliferate and ensure both immunological and hematological reconstitution. The transplant can use allogeneic stem cells (allograft) or the patient's own stem cells (autograft). This technique has been developed in France for about twenty years. In 1995, 621 allografts and 1,952 autografts were performed, placing France at the forefront in Europe. This technique, which is increasingly used in hematological disorders, requires hospital care but also management by the general practitioner, who is often the first to encounter complications related to this technique. The goal of the transplant is threefold:

- To treat the underlying hematological disorder through the transplant conditioning, which often includes total body irradiation (TBI) combined with myeloablative chemotherapy.
- To replace the pathological hematopoietic cells with normal stem cells obtained from the donor.
- To fight the hematological disorder through an immunological effect specific to the allograft: the Graft-versus-Leukemia (GVL) effect, which is related to the immunocompetent cells of the donor, thus reducing the risk of relapse after transplantation.



Bone marrow transplantation (BMT) is a complex and high-risk procedure, typically reserved for patients who do not have any other viable therapeutic options. It is often considered when the underlying disease presents a life-threatening risk in the short, medium, or long term. The decision to perform such a procedure depends on several factors, including the patient's overall health, the type of disease, and the availability of a suitable donor.

28.1.Allograft

An allograft refers to a transplant of hematopoietic stem cells (HSC) from a donor, typically someone other than the patient, such as a sibling or an unrelated donor. Allografting is used in various clinical scenarios, particularly in cases of hematologic malignancies (blood cancers such as leukemia, lymphoma, and myelodysplastic syndromes). In these cases, the transplant is aimed at replacing the patient's defective or malignant hematopoietic system with healthy cells from the donor.

themain indications for allograftingcan be broadly classified as follows:

1. **Hematologic malignancies**: For patients with blood cancers, the primary goal is to eliminate or reduce the tumor burden to the lowest possible level before performing the transplant. The procedure is generally considered after the patient reaches either a first complete remission (CR1) or a second complete remission (CR2), as long as the disease is in remission and the patient's clinical status allows for it. In these cases, the smaller the tumor mass at the time of transplant, the lower the risk of relapse. Therefore, in malignant hematopathies, achieving a minimal residual disease state is a critical factor in determining transplant eligibility. The decision to perform the transplant is influenced by factors like the type of malignancy, the patient's response to previous treatments, and their general prognosis.
2. **Hereditary hematological disorders**: In cases of inherited blood disorders such as sickle cell anemia, thalassemia, and other congenital bone marrow failure syndromes, the transplant serves to replace the patient's defective hematopoietic stem cells with healthy donor cells. This not only addresses the quantitative deficiencies (e.g., low red blood cell production in sickle cell disease) but also provides the patient with normal, functional cells that can produce the necessary blood components and enzymes the body is missing. In this context, the transplant is more about replacing the defective genetic material in the hematopoietic cells, potentially providing a cure for the disorder.



3. However, despite its potential benefits, allografting comes with significant risks. One of the most critical complications is graft-versus-host disease (GVHD)**,** where the donor's immune cells attack the recipient's tissues. This risk is particularly high in mismatched or unrelated donor transplants, and the severity of GVHD can impact the success and overall survival of the transplant. Other complications include infections, organ damage, and transplant rejection.
4. **Age and eligibility for allograft**

   Because of the complexity and risks associated with the procedure, there are strict criteria regarding the age and overall health of the recipient. In general, allograft transplants are considered most successful in patients under 50 years old. Older patients face an increased risk of complications, particularly related to the conditioning regimen (which often includes chemotherapy and total body irradiation), the recovery of the immune system, and the likelihood of chronic GVHD. Therefore, age remains one of the key factors in determining eligibility for an allograft.

The recipient's general health and presence of other comorbid conditions, such as heart disease, kidney failure, or infections, also play a crucial role in the decision-making process. The patient must be able to withstand the intense treatment protocol and manage the post-transplant recovery process.

28.2.Autograft

Compared to allografting, an autograft involves the use of the patient's own hematopoietic stem cells. While this approach reduces the risk of graft-versus-host disease (GVHD) that is seen with allografts, there remains a theoretical risk of contaminating the graft with tumor cells, especially in cases of hematologic malignancies. To mitigate this risk, ex vivo purging of tumor cells is often performed, which involves isolating and removing any malignant cells from the stem cell graft before it is re-infused into the patient. This technique aims to minimize the chance that residual disease will be transplanted along with the healthy stem cells.

The primary objective of an autograft is to deliver the necessary myeloablative treatment to eradicate the underlying hematological disease (such as leukemia, lymphoma, or myeloma). The myeloablative treatment typically includes chemotherapy or total body irradiation (TBI) to destroy the patient's diseased bone marrow, after which the patient's own hematopoietic stem cells are reinfused to reconstitute thehematopoietic system. The stem cells begin to repopulate the bone marrow, leading to the restoration of normal blood cell production.



One of the significant advantages of autografting is that, since the patient's own cells are used, the risk of rejection is virtually nonexistent, and there is no issue with graft-versus-host disease**.** This makes the recovery process potentially less complicated than with an allograft. However, as the graft is derived from the patient's own stem cells, the major challenge is the possibility of residual disease. In cases of hematologic malignancies, if there is a high level of contamination with malignant cells, the disease may relapse after transplantation. For this reason, extensive screening and purging techniques are employed before the transplant to ensure that the graft is as clean as possible.

The indications for autograft are similar to those for allograft but are generally more appropriate when the hematopoietic stem cells are theoretically healthy—meaning the patient's bone marrow or blood is not significantly compromised by disease or preexisting conditions. Autografts are commonly used in cases where the patient is in remission from their malignancy and the goal is to eliminate any remaining disease through myeloablative therapy, rather than to replace an entirely dysfunctional hematopoietic system. In diseases like multiple myeloma**,** non-Hodgkinlymphoma**,** and acute lymphoblastic leukemia (in remission), autografts can offer an effective means of achieving long-term remission.

Another key consideration is the age and overall health of the patient. Older patients or those with significant comorbidities may not be suitable candidates for the intense pre-transplant conditioning required in an autograft. As with all transplant types, careful evaluation of the patient's overall health, the likelihood of disease relapse, and the potential for long-term survival is critical in determining whether an autograft is the best treatment option.

In summary, autografting is a treatment method in which a patient's own hematopoietic stem cells are used to repopulate the bone marrow after myeloablative therapy. It is mainly indicated for patients whose hematopoietic system is still theoretically healthy, with a focus on eradicating the underlying disease through chemotherapy or radiation. While autografting carries fewer risks of rejection and GVHD, it does not eliminate the potential for relapse if malignant cells are present in the graft. Therefore, careful patient selection, tumor cell purging, and close monitoring are essential to achieving the best outcomes.

28.3.Peripheral Hematopoietic Stem Cells

This technique is currently primarily used for autografts. After mobilization by chemotherapy and/or hematopoietic growth factors, hematopoietic stem cells can be found in the circulating blood. These stem



cells can be collected through cytapheresis. This technique allows for the collection of grafts that are quantitatively and qualitatively richer, avoids the need for general anesthesia, and theoretically provides a graft less contaminated by tumor cells. The use of peripheral stem cells from blood is particularly beneficial in reducing the risks associated with bone marrow collection and in providing a better-quality graft for the patient.

28.4.Cord Blood

Currently, a cord blood bank is also being established. Cord blood, being rich in hematopoietic stem cells and not fully immunocompetent, can allow for transplantation even when there is an HLA disparity between the donor and recipient. This is especially valuable for patients who do not have a fully matched donor available. The cells in cord blood are less mature and more adaptable, which can enable successful transplantation despite some degree of HLA mismatch.

28.5.Quality control

The quality of the marrow graft is evaluated by counting the mononuclear cells of the graft during the collection process. Cultures of progenitor cells and the count of cells bearing the **CD34 antigen**—a marker for hematopoietic stem cells—are used to assess the quality of the collected graft. These quality controls are particularly important in autografts, where the hematopoietic stem cells may have been altered or damaged due to prior chemotherapy and/or radiation therapy. The integrity of these stem cells is crucial for the success of the transplant, as damaged or insufficient stem cells could lead to poor hematopoietic reconstitution or increased risk of disease relapse. Therefore, these tests ensure that the collected graft is viable and has a high potential for engraftment.

In summary, peripheral hematopoietic stem cell collection via cytapheresis allows for a more efficient, less invasive method of obtaining stem cells for autografts. Similarly, the establishment of cord blood banksoffers an alternative source of stem cells for patients who may have difficulty finding a fully matched donor. Ensuring the quality of the graft through rigorous testing, such as CD34 cell counting and progenitor cell culture, is essential to optimizing the chances of a successful transplant, particularly in autografting scenarios where prior treatments may have compromised the stem cells' quality.



28.6.Complications

Although bone marrow transplantation allows for the cure of an increasing number of malignant and non-malignant diseases, both acute andchronic complicationsmay arise during the course of the treatment. These complications are primarily due to several factors, including the graft-versus-host disease(GVHD), which occurs only in the case of **allogeneic** transplants, and the toxicity of the conditioning regimen**.**

A/ Graft-versus-host disease (GVHD)

GVHD is a major complication unique to allogeneic transplants, where the donor's immune cells (graft) recognize the recipient's (host) tissues as foreign and mount an immune response against them. This immune reaction can affect various organs, especially the skin, liver, and gastrointestinal tract, causing a range of symptoms from mild rashes and digestive issues to severe organ failure. GVHD is classified into two forms:

1. **Acute GVHD**: This occurs in the first 100 days following the transplant and is characterized by symptoms such as skin rash, diarrhea, and liver dysfunction. In severe cases, acute GVHD can lead to organ failure, significantly affecting the patient's survival.
2. **Chronic GVHD**: This can develop after the first 100 days and can last for months or even years. It often affects the skin, eyes, mouth, and lungs, leading to long-term disabilities and requiring ongoing management. Chronic GVHD can severely affect the patient's quality of life and may be difficult to treat.

GVHD is one of the most challenging complications in allogeneic transplants, requiring intensive immunosuppressive therapy to prevent or treat the disease. However, such treatments increase the risk of infections and other complications, creating a delicate balance between controlling GVHD and preserving the immune system.

B/ Toxicity of Conditioning Regimen

The **conditioning regimen**—which typically includes chemotherapy and/or radiation therapy—is used to destroy the patient's existing bone marrow and make space for the transplanted stem cells. While this treatment is essential for ensuring the success of the transplant, it also carries significant **toxicity**. The high doses of chemotherapy and radiation used can cause a variety of side effects, including:



- **Hematologic toxicity**: The destruction of bone marrow cells may lead to prolonged periods of low blood cell counts (anemia, neutropenia, thrombocytopenia), which increases the risk of infections, bleeding, and fatigue.
- **Organ toxicity**: Chemotherapy and radiation can also damage other organs such as the liver, kidneys, heart, and lungs. For example, patients may experience liver dysfunction, kidney failure, or cardiotoxicity, which may require additional medical interventions.
- **Mucositis and gastrointestinal toxicity**: Chemotherapy can cause severe mucositis, leading to painful inflammation of the mouth, throat, and intestines. This can make eating, swallowing, and digestion difficult and can also lead to infection.
- **Endocrine dysfunction**: The conditioning regimen can cause long-term damage to the endocrine system, resulting in hormonal imbalances such as hypothyroidism, adrenal insufficiency, or growth hormone deficiency.

29.Recommendations and guidelines for future students considering a career in hematology

1. **Strong foundation in basic sciences**: A solid understanding of biology, particularly cell biology, biochemistry, and genetics, is essential. Hematology involves complex cellular processes and molecular biology, and mastering these concepts will be fundamental to your success.
2. **Stay updated with advances**: Hematology is a rapidly evolving field with new discoveries in diagnostics, treatment options, and technologies. Keep yourself informed about the latest research, clinical trials, and advancements in blood disorders and treatments.
3. **Engage in practical experience**: Gaining hands-on experience in laboratory settings, clinical environments, or research projects is crucial. Participating in internships or shadowing hematologists will provide valuable exposure to the daily tasks and challenges of the field.
4. **Develop strong analytical skills**: Hematology often requires careful analysis of complex data, such as blood tests, bone marrow samples, and genetic information. Cultivate your ability to interpret lab results, understand diagnostic criteria, and make informed decisions based on evidence.
5. **Communication and collaboration**: As a hematologist or a researcher, you will work with a multidisciplinary team of doctors, nurses, researchers, and patients. Strong communication skills are necessary to explain complex medical information clearly and collaborate effectively with colleagues.



6. **Specialize and find your focus**: Hematology is a broad field, encompassing benign and malignant blood disorders, such as anemia, leukemia, and clotting disorders. Identify an area of interest—whether it's research, clinical practice, or specific subfields like hematopoietic stem cell transplantation—and focus your efforts on developing expertise in that area.
7. **Understand the importance of patient care**: While technical knowledge is crucial, always remember the human aspect of the field. Hematology deals with conditions that can affect patients' quality of life. Empathy, patience, and a strong commitment to patient care are essential qualities.
8. **Pursue advanced education and training**: Hematology often requires advanced training, including medical school, fellowships, or specialized graduate programs. Pursue continuous education to deepen your expertise and stay competitive in this evolving field.
9. **Ethical considerations**: As with all areas of medicine, practicing hematology involves ethical considerations, especially when dealing with vulnerable populations, managing chronic conditions, or navigating the challenges of blood transfusions, stem cell treatments, and genetic therapies. Be prepared to make informed and compassionate ethical decisions.
10. **Foster a passion for research**: Hematology is not only about treating patients but also advancing medical knowledge. If you're interested in research, focus on gaining expertise in laboratory techniques, clinical trials, and understanding the molecular mechanisms of blood disorders to contribute to the field's growth.
11. **Master laboratory techniques**: Hematology heavily relies on laboratory investigations, including blood smears, flow cytometry, molecular diagnostics, and bone marrow biopsies. Acquiring proficiency in these techniques will enhance both your research and diagnostic capabilities.
12. **Develop critical thinking and problem-solving skills**: Many hematological conditions present with overlapping symptoms and require careful differential diagnosis. Cultivate strong analytical thinking to evaluate clinical cases, interpret test results, and determine appropriate treatment plans.
13. **Gain exposure to transfusion medicine**: Blood transfusions, platelet transfusions, and plasma exchanges are key aspects of hematology. Understanding blood banking, donor compatibility, and transfusion reactions will prepare you for clinical and emergency situations.
14. **Stay proficient in genetics and immunology**: Many hematological disorders, such as sickle cell disease, hemophilia, and leukemia, have genetic and immunological components. A strong grasp of molecular biology, gene therapy, and immunohematology will be advantageous.
15. **Familiarize yourself with stem cell and bone marrow transplantation**: Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure used in conditions like leukemia and lymphoma.

Understanding donor selection, graft-versus-host disease (GVHD), and post-transplant care will be essential if you plan to specialize in this area.

16. **Work on data interpretation and statistical skills**: Research in hematology often involves analyzing large datasets, survival rates, and treatment outcomes. Developing skills in biostatistics and using software for data analysis (such as SPSS or R) will strengthen your ability to conduct clinical research.
17. **Stay informed on emerging therapies**: The field of hematology is advancing with new treatments such as monoclonal antibodies, CAR-T cell therapy, gene editing (CRISPR), and targeted molecular therapies. Keeping up with novel treatment strategies will allow you to provide better care and contribute to future medical advancements.
18. **Develop skills in personalized and precision medicine**: Hematology is increasingly moving towards personalized treatment plans based on a patient's genetic profile and disease markers. Learning about precision medicine and its application in hematological disorders will be beneficial in modern clinical practice.
19. **Understand global and public health perspectives**: Blood disorders vary in prevalence worldwide, with conditions like sickle cell disease being more common in certain regions. Understanding epidemiology, health policies, and global efforts in hematology (such as blood donation programs and access to treatment) will provide a broader perspective on your role in the field.
20. **Join professional organizations and networks**: Engaging with hematology societies, such as the American Society of Hematology (ASH) or the European Hematology Association (EHA), will help you access the latest research, attend conferences, and network with experts in the field.
21. **Pursue clinical and research fellowships**: Specializing in hematology requires further training beyond medical or graduate school. Seek fellowship opportunities that provide in-depth exposure to clinical cases, advanced research, and specialized treatments in hematology.
22. **Work on resilience and emotional intelligence**: Hematology involves managing life-threatening diseases such as leukemia and lymphoma. Dealing with critically ill patients and making difficult treatment decisions requires emotional resilience, strong ethics, and the ability to support patients and their families through challenging situations.
23. **Emphasize preventive hematology**: While hematology often focuses on treating existing conditions, preventive measures such as newborn screening for sickle cell disease, vaccination

programs for patients with immunodeficiencies, and lifestyle modifications to prevent clotting disorders are equally important.

24. **Improve leadership and teaching abilities**: Whether in a clinical, academic, or research setting, leadership skills will help you manage teams, contribute to medical education, and guide future hematologists. Consider mentoring students, giving presentations, and participating in academic discussions.
25. **Adapt to technological advancements**: Artificial intelligence (AI), machine learning, and automation are transforming diagnostics and patient care in hematology. Familiarize yourself with new technologies, electronic medical records, and digital pathology to stay ahead in the field.
26. Develop expertise in precision medicine, particularly in targeted therapies.
27. Stay informed about advancements in immunotherapy for hematologic cancers.
28. Learn about strategies to manage the side effects of hematology treatments.
29. Integrate artificial intelligence tools in clinical data analysis and laboratory results.
30. Explore combination therapies, such as chemotherapy and immunotherapy, in hematologic cancers.
31. Focus on managing complications related to blood transfusion treatments.
32. Stay updated on treatments for coagulation disorders, such as hemophilia.
33. Pay attention to pharmacovigilance, particularly for drugs used in hematology.
34. Integrate personalized medicine strategies in the treatment of leukemia and lymphoma.
35. Participate in specialized scientific discussions and forums focused on blood diseases.
36. Join collaborative international and inter-university research projects on hematologic diseases.
37. Conduct research on new diagnostic approaches for the early detection of blood cancers.
38. Explore molecular diagnostic techniques for genetic blood disorders.
39. Integrate medical ethics into teaching hematology and transfusion medicine.
40. Develop skills in managing rare blood diseases, such as thalassemia.
41. Learn how to manage palliative care for patients with advanced hematologic conditions.
42. Study the challenges related to access to hematology care in developing countries.
43. Be aware of the importance of genetic testing for diagnosing and treating hematologic cancers.
44. Stay updated on treatment protocols in clinical trials (Phase I, II, and III).
45. Learn how to assess the risks of experimental treatments in hematology.
46. Participate in training on molecular biology technologies and their applications in hematology.
47. Stay engaged with research on the molecular mechanisms of blood disorders.



48. Study the role of bioinformatics in analyzing large-scale hematology data sets.
49. Understand the role of stem cells in regenerative hematology and tissue repair.
50. Keep up with the latest advancements in gene therapy for blood diseases.
51. Explore new techniques in gene editing, such as CRISPR, for treating hematologic disorders. De
52. velop a deep understanding of the immune system and its role in hematology.
53. Attend conferences and symposia to expand your network in the hematology community.
54. Become proficient in molecular cytogenetics for diagnosing blood cancers.
55. Study the role of tumor microenvironments in hematologic malignancies.
56. Develop expertise in hematopoiesis and its disruptions in blood disorders.
57. Understand the principles of clinical trial design in hematology research.
58. Learn about hematological impacts of viral infections such as HIV and hepatitis.
59. Pursue training in clinical genetics, particularly in relation to hematologic diseases.
60. Keep current on new diagnostic techniques, such as next-generation sequencing (NGS) for blood disorders.
61. Develop skills in interpreting complex genetic and molecular diagnostic results.
62. Collaborate with multidisciplinary teams, including oncologists, immunologists, and pathologists.
63. Study the genetic predisposition and inheritance patterns of blood disorders.
64. Investigate the relationship between blood disorders and environmental factors.
65. Understand the psychological aspects of treating patients with chronic blood diseases.
66. Explore the application of nanotechnology in hematology for improved diagnostics and treatment delivery.
67. Study the global burden of hematologic diseases and their public health impact.
68. Learn about the challenges of bone marrow donor matching and transplant procedures.
69. Stay informed about the role of cancer genomics in hematologic malignancies.
70. Participate in workshops on advanced hematology laboratory techniques.
71. Understand the principles of transfusion medicine, including blood type matching and donor selection.
72. Pursue certifications in specialized techniques such as flow cytometry or bone marrow biopsy.
73. Study the relationship between blood disorders and autoimmune diseases.
74. Stay informed on the latest in molecular diagnostics for myelodysplastic syndromes (MDS).
75. Master techniques in blood cell counting, blood smear analysis, and reticulocyte studies.
76. Focus on the development of targeted therapies for rare blood cancers.



77. Learn the latest methods in platelet function testing and clotting analysis.
78. Participate in clinical studies that assess new blood cancer treatments.
79. Stay engaged with the hematology community by joining online forums and discussion groups.
80. Be familiar with blood disorder management in pediatric populations.
81. Develop an understanding of hemoglobinopathies, such as sickle cell disease and thalassemia.
82. Explore the ethical considerations of gene therapy in hematology.
83. Learn to navigate patient consent in clinical trials, particularly for vulnerable populations.
84. Stay updated on the latest research in lymphoma and myeloma treatments.
85. Develop expertise in laboratory-based diagnostic techniques, including PCR and immunohistochemistry.
86. Study the role of epigenetics in blood diseases and hematologic malignancies.
87. Learn about emerging biomarkers for blood cancers.
88. Understand the role of inflammation in hematologic diseases and treatments
89. Keep abreast of new approaches in preventing thrombotic diseases.
90. Explore the role of hematology in precision medicine and its application to rare diseases.
91. Develop leadership skills by mentoring junior researchers or medical students.
92. Stay informed on the intersection of hematology and geriatrics, especially in aging populations.
93. Study the role of lifestyle factors, such as diet and exercise, in preventing blood disorders.
94. Pursue interdisciplinary collaborations to enhance clinical and research outcomes in hematology
95. Focus on understanding the pathology of hematologic malignancies at the molecular and cellular levels.
96. Study the impact of lifestyle and environmental exposures on blood cancers.
97. . Work on improving patient outcomes in hematology through evidence-based practices.

98. Be proactive in learning about novel blood cancer treatments through online courses and webinars.
99. Learn how to balance the technical and human aspects of hematology care.



30.Safety recommendations for future students pursuing a career in hematology

1. **Follow biosafety protocols**: Hematology laboratories handle blood samples, bone marrow aspirates, and other biological specimens that may carry infectious agents. Always adhere to biosafety guidelines, including wearing appropriate personal protective equipment (PPE) such as gloves, lab coats, and face shields.
2. **Practice proper hand hygiene**: Frequent handwashing with soap and water or using alcohol-based hand sanitizers is crucial to prevent the spread of infections, especially when working with patient samples.
3. **Handle needles and sharps with care**: Blood collection, bone marrow aspiration, and other procedures involve the use of needles. Always use proper techniques for handling, recapping (if necessary), and disposing of sharps in designated biohazard containers to prevent needlestick injuries.
4. **Be aware of bloodborne pathogens**: Blood samples may contain viruses such as HIV, Hepatitis B (HBV), and Hepatitis C (HCV). Ensure that you receive proper training on handling potentially infectious materials and follow universal precautions to minimize exposure risks.
5. **Use a fume hood or biosafety cabinet when necessary**: Certain hematology procedures involve chemicals or biological agents that may produce aerosols. Work within a biosafety cabinet when handling potentially hazardous substances to prevent inhalation exposure.
6. **Properly dispose of biological waste**: Blood-soaked materials, used gloves, contaminated pipettes, and other biomedical waste should be disposed of according to institutional and national waste management policies. Do not dispose of biohazardous materials in regular trash bins.
7. **Understand radiation safety in imaging studies**: Some hematology-related diagnostics, such as bone marrow biopsies with imaging guidance, may involve exposure to X-rays or radiation. Follow safety protocols and wear protective shielding if working near radiation-emitting equipment.
8. **Store and handle reagents safely**: Hematology involves the use of chemicals such as fixatives, stains (e.g., Wright-Giemsa stain), and anticoagulants. Always read safety data sheets (SDS) before handling reagents, wear appropriate protective gear, and ensure proper ventilation in the workspace.
9. **Take precautions during blood transfusion procedures**: If involved in transfusion medicine, always follow strict protocols for crossmatching, blood type verification, and patient identification to prevent transfusion reactions or mismatches.

10. **Minimize the risk of allergic reactions**: Some hematology reagents and latex gloves may cause allergic reactions. If you or a colleague have known allergies, use non-latex gloves and alternative reagents when possible.
11. **Avoid eating or drinking in the laboratory**: Never consume food or beverages in areas where biological samples or chemicals are handled. This prevents accidental ingestion of hazardous substances.
12. **Stay updated on emergency procedures**: Familiarize yourself with the location of eyewash stations, safety showers, fire extinguishers, and first aid kits in your laboratory or workplace. Know the emergency contact numbers and protocols in case of accidents or exposure incidents.
13. **Receive proper vaccinations**: Healthcare and laboratory workers in hematology should be vaccinated against Hepatitis B and other infectious diseases to reduce the risk of occupational exposure.
14. **Monitor for Signs of Fatigue or Burnout**: Working long hours in a clinical or research setting can lead to fatigue, which increases the risk of errors and accidents. Ensure adequate rest, take breaks when needed, and prioritize mental and physical well-being.
15. **Follow ethical and patient safety guidelines**: If working in clinical hematology, always maintain patient confidentiality, obtain informed consent when required, and ensure that all procedures follow ethical standards to protect patient rights and safety.



31.Useful informations

31.1.Basic terms

- Hematopoiesis**:** The process of blood cell formation, occurring in the bone marrow.
- Hemoglobin (Hb): A protein in red blood cells that carries oxygen.
- Hematocrit (Hct): The percentage of blood volume occupied by red blood cells.
- Leukocytes: White blood cells responsible for immune response.
- Platelets (Thrombocytes): Cell fragments involved in blood clotting.
- Anemia: A condition where there is a deficiency of red blood cells or hemoglobin, leading to reduced oxygen delivery to tissues.
- Polycythemia: An abnormal increase in the number of red blood cells.
- Leukemia: A cancer of the blood or bone marrow characterized by an overproduction of abnormal white blood cells.

31.2.Blood disorders:

- Thrombocytopenia**:** A condition characterized by low platelet count.
- Thrombocytosis**:** An abnormal increase in platelet count.
- Sickle Cell Disease**:** A genetic disorder where red blood cells are abnormally shaped, leading to various complications.
- Hemophilia**:** A genetic disorder where blood doesn't clot properly due to a deficiency of clotting factors.
- Iron Deficiency Anemia**:** A type of anemia caused by insufficient iron levels.
- Pernicious Anemia**:** A type of anemia caused by the inability to absorb vitamin B12.
- Myelodysplastic Syndromes (MDS**)**: A group of disorders caused by poorly formed or dysfunctional blood cells.

31.3.Laboratory tests:

- Complete Blood Count (CBC)**:** A test that measures the levels of red blood cells, white blood cells, hemoglobin, hematocrit, and platelets.



- Reticulocyte Count**:** A measure of the number of young red blood cells in the blood, often used to assess bone marrow function.
- Prothrombin Time (PT)**:** A test that measures the time it takes for blood to clot, often used to evaluate clotting function.
- Partial Thromboplastin Time (PTT)**:** A test that assesses the intrinsic pathway of the clotting cascade.
- Bone Marrow Biopsy**:** A procedure to collect and examine bone marrow to diagnose hematologic disorders.

31.4.Clotting factors:

- Factor VIII**:** A clotting factor deficient in hemophilia A.
- Factor IX**:** A clotting factor deficient in hemophilia B.
- Thromboplastin**:** A protein released from platelets and other tissues, essential for blood clotting.

31.5.Transudate and exudate

A **transudate** is a fluid that accumulates in body cavities, such as the pleural or peritoneal cavity, due to imbalances in hydrostatic or osmotic pressures rather than inflammation. It is typically clear, low in protein (less than 3 g/dL), low in specific gravity (less than 1.012), and contains fewer cells. Common causes of transudate include heart failure, liver cirrhosis, and nephrotic syndrome. In contrast, an exudate forms due to inflammation, often triggered by infection, injury, or malignancy. It is rich in proteins, cells, and sometimes pathogens, with high protein content (greater than 3 g/dL), high specific gravity (greater than 1.020), and a high cell count, especially white blood cells. Exudates are commonly seen in conditions such as infections (e.g., pneumonia) or cancers, where tissue damage and immune response contribute to fluid accumulation.

31.6.Serum and plasma

Plasma is the liquid portion of blood that remains when blood cells are removed but the clotting factors, such as fibrinogen, are still present. It is obtained by collecting blood into a tube containing an anticoagulant (like EDTA or heparin), which prevents clotting. After centrifugation, the plasma is separated from the formed elements. Plasma contains water, electrolytes, proteins (such as albumin and fibrinogen), nutrients, hormones, and waste products. In contrast, serum is the liquid portion of blood after the clotting factors have been removed, following coagulation. It is essentially plasma without the clotting proteins. Serum is obtained by collecting blood in a tube without anticoagulants, allowing it to clot, and then centrifuging to separate the serum from the clot. While similar to plasma, serum lacks fibrinogen and other clotting factors.

31.7.Additional informations

1. Hematology

The branch of medicine that deals with the study of blood, blood-forming organs (such as bone marrow), and blood diseases.

2. Hemoglobin (Hb)

A protein found in red blood cells responsible for transporting oxygen from the lungs to tissues and carbon dioxide from tissues to the lungs.

3. Hematopoiesis

The process of blood cell formation (red blood cells, white blood cells, platelets) in the bone marrow.

4. Anemia

A condition where there is a reduction in the number of red blood cells or hemoglobin concentration, leading to a decreased ability to transport oxygen.

5. Leukemia

A type of cancer that affects blood cells, characterized by the uncontrolled production of abnormal white blood cells in the bone marrow.

6. Thrombocytopenia

A condition characterized by a low platelet count, increasing the risk of bleeding.

7. Polycythemia

An excessive increase in the number of red blood cells, which thickens the blood and raises the risk of thrombosis.

8. Hemophilia

A genetic disorder that impairs normal blood clotting, leading to increased bleeding tendencies.

9. Thrombosis

The abnormal formation of a blood clot in a blood vessel, which can obstruct blood flow and lead to complications such as stroke or heart attack.

10. Myelodysplastic Syndrome

A group of blood disorders where the bone marrow produces abnormal blood cells that do not function properly, often leading to bone marrow failure.

11. White Blood Cells (Leukocytes)

Blood cells that are involved in the body's defense against infections and diseases. They are classified as neutrophils, lymphocytes, monocytes, eosinophils, and basophils.

12. Granulocytes

A type of white blood cell that contains granules in their cytoplasm. They play a crucial role in the immune response against bacterial infections.

13. Platelets (Thrombocytes)

Small blood cells that are involved in clotting and form blood clots to stop bleeding.

14. Bone Marrow

Spongy tissue found inside bones, responsible for producing blood cells (hematopoiesis).

15. Hematocrit

A measure of the percentage of red blood cells in the blood. It is used to assess anemia or polycythemia.

16. Sickle Cell Disease

A genetic disorder characterized by abnormally shaped red blood cells (sickle-shaped) that can obstruct blood vessels, causing pain, infections, and organ damage.

17. Pancytopenia

A reduction in all types of blood cells (red blood cells, white blood cells, and platelets) in the blood.

18. Hemolysis



The premature destruction of red blood cells, which can lead to an abnormal increase in bilirubin levels in the blood and cause jaundice.

19. Bilirubin

A byproduct of red blood cell breakdown in the liver, which can accumulate in the blood during hemolysis or liver dysfunction, leading to jaundice.

20. Bone Marrow Aspiration

A diagnostic procedure where a sample of bone marrow is taken to analyze the blood cells present, commonly used for diagnosing blood cancers like leukemia.

21. Erythropoiesis

The production of red blood cells, primarily regulated by erythropoietin, a hormone produced by the kidneys in response to low oxygen levels.

22. Coagulation

The process by which blood forms clots to stop bleeding. It involves a series of proteins called clotting factors.

23. D-dimers

Byproducts of the breakdown of blood clots, often used as markers to detect clotting disorders such as deep vein thrombosis or pulmonary embolism.

24. Blood Transfusion

A medical procedure in which blood products (such as red blood cells, platelets, or plasma) are given to a patient, typically to replace lost blood.

25. Crossmatch

A test performed before blood transfusions to ensure compatibility between the donor's and recipient's blood to prevent immune reactions.

26. Lymphoma

A cancer of the lymphocytes (a type of white blood cell) that affects the lymphatic system and can cause swollen lymph nodes and weight loss.

27. Anisocytosis

The presence of red blood cells of varying sizes in the blood, which may indicate different forms of anemia.

28. Reticulocytes

Immature red blood cells that still contain RNA. Their count in the blood can indicate the production of new red blood cells.

29. Prothrombin

A plasma protein that, once activated, becomes thrombin, a key component in blood clot formation.

30. Thrombophilia

A blood disorder that increases the tendency to develop abnormal blood clots. It can be caused by genetic mutations or environmental factors.

31. Gaucher Disease

A rare genetic disorder where abnormal cells accumulate in the liver, spleen, and bone marrow, disrupting normal organ function.

32. Chemotherapy Induction

The initial phase of leukemia treatment where medications are used to rapidly reduce the number of cancerous cells in the blood and bone marrow.

33. Thrombocytosis

An elevated platelet count, which can increase the risk of clotting and lead to complications like stroke or deep vein thrombosis.

34. Platelet Transfusion

A medical procedure used to treat thrombocytopenia, where platelet products are transfused to a patient with a low platelet count.

35. Cerebral Infarction (Stroke)

Obstruction of a blood vessel in the brain, often due to a clot, depriving brain cells of oxygen and leading to neurological deficits.

36. Myeloma

A cancer of plasma cells in the bone marrow that affects the production of normal blood cells, leading to bone pain, anemia, and kidney dysfunction.

37. Bone Marrow Biopsy

A procedure in which a small sample of bone marrow is extracted to assess blood cell production, diagnose blood disorders, and check for cancers like leukemia or lymphoma.

38. Hemolytic Anemia

A type of anemia caused by the premature destruction of red blood cells, which leads to a shortage of functional red blood cells in circulation.



39. Plasmapheresis

A therapeutic procedure that involves removing plasma from the blood, usually to treat conditions like autoimmune diseases or to remove harmful antibodies.

40. Iron Deficiency Anemia

A common form of anemia caused by a lack of iron in the body, leading to reduced hemoglobin production and symptoms like fatigue and pale skin.

41. Thromboembolism

The obstruction of a blood vessel by a clot that has traveled from another part of the body, such as a deep vein thrombosis (DVT) that moves to the lungs (pulmonary embolism).

42. Factor Deficiency

A condition where one of the clotting factors in the blood is deficient or absent, leading to bleeding disorders such as hemophilia.

43. Autoimmune Hemolytic Anemia

Anemia caused by the immune system attacking and destroying its own red blood cells.

44. Acute Myeloid Leukemia (AML)

A fast-growing cancer of the blood and bone marrow, characterized by the uncontrolled growth of immature white blood cells.

45. Chronic Myelogenous Leukemia (CML)

A type of leukemia that starts in the blood-forming cells of the bone marrow and leads to high numbers of abnormal white blood cells.

46. Von Willebrand Disease

An inherited bleeding disorder caused by a deficiency of von Willebrand factor, a protein needed for blood clotting.

47. Fibrinogen

A plasma protein involved in blood clotting that is converted to fibrin to form a clot at the site of injury.

48. Hemolytic Uremic Syndrome (HUS)

A rare condition that involves the destruction of red blood cells, which leads to kidney failure, and is often triggered by an infection like E. coli.

49. Hemarthrosis

Bleeding into a joint cavity, which is commonly seen in individuals with hemophilia or other clotting disorders.

50. Hypereosinophilia

An abnormal increase in eosinophils (a type of white blood cell) often seen in allergic reactions, parasitic infections, or certain blood cancers.

51. Thrombosis

The formation of a blood clot inside a blood vessel, which can obstruct blood flow and cause complications like heart attacks or strokes.

52. Idiopathic Thrombocytopenic Purpura (ITP)

A disorder in which the immune system destroys platelets, leading to easy bruising, bleeding, and low platelet counts.

53. Lymphocyte

A type of white blood cell that plays a major role in the immune system, including B cells and T cells.

54. Hemochromatosis

A genetic disorder where the body absorbs too much iron from food, leading to excess iron storage in organs, which can damage them over time.

55. Eosinophilia

An elevated level of eosinophils, which are a type of white blood cell often associated with allergic reactions, asthma, or parasitic infections.

56. Blood Cultures

A laboratory test used to detect the presence of bacteria or fungi in the blood, commonly used to diagnose sepsis or bloodstream infections.

57. Hemoconcentration

An increase in the concentration of red blood cells and other blood components, often due to dehydration or fluid loss.

58. Sideroblastic Anemia

A type of anemia where the bone marrow produces ringed sideroblasts (abnormal red blood cell precursors), often due to a defect in iron metabolism.

59. Neutropenia

A condition characterized by an abnormally low number of neutrophils (a type of white blood cell), making individuals more susceptible to infections.

60. Lymphadenopathy

Swelling of lymph nodes, often indicative of infection, lymphoma, or other diseases affecting the lymphatic system.



61. Cryoprecipitate

A component of blood plasma that is rich in clotting factors, including fibrinogen, used to treat bleeding disorders.

62. Hemoglobinopathies

Genetic disorders that affect the structure or production of hemoglobin, such as sickle cell disease or thalassemia.

63. Leukopenia

A reduced white blood cell count, often seen in infections, autoimmune diseases, or as a side effect of certain medications.

64. Polycythemia Vera

A type of blood cancer that causes the bone marrow to produce too many red blood cells, which thickens the blood and increases the risk of clots.

65. Hypochromic Anemia

A form of anemia in which red blood cells are paler than usual due to a low hemoglobin content, often caused by iron deficiency.

66. Hemoglobin A1c

A test that measures the average blood sugar levels over the past 2-3 months, commonly used in diagnosing and monitoring diabetes.

67. Chronic Lymphocytic Leukemia (CLL)

A slow-growing cancer of the blood and bone marrow that affects lymphocytes, leading to an overproduction of abnormal white blood cells.

68. G6PD Deficiency

A genetic enzyme deficiency that can cause hemolytic anemia, typically triggered by infections, certain medications, or foods such as fava beans.

69. Thrombocytosis

An abnormally high platelet count in the blood, which can lead to an increased risk of blood clots and complications such as strokes or heart attacks.

70. Bone Marrow Failure

A condition in which the bone marrow fails to produce sufficient numbers of blood cells, leading to anemia, infections, and bleeding.



71. Paroxysmal Nocturnal Hemoglobinuria (PNH)

A rare, acquired disorder in which red blood cells break down prematurely, leading to anemia, fatigue, and an increased risk of blood clots.

72. Hemorrhagic Diathesis

A condition that predisposes an individual to spontaneous bleeding, often due to a defect in the clotting cascade or platelet function.

73. Serum Iron Test

A blood test used to measure the amount of iron in the blood, often used to diagnose iron deficiency anemia or iron overload conditions.

74. Thrombotic Thrombocytopenic Purpura (TTP)

A rare, life-threatening blood disorder characterized by blood clot formation in small blood vessels, leading to low platelet counts, anemia, and organ damage.

75. Folate Deficiency Anemia

Anemia caused by insufficient folic acid (vitamin B9), which is necessary for the production of red blood cells. It can lead to fatigue and weakness.

76. Chronic Anemia

Anemia that persists over a long period, often caused by chronic diseases like kidney disease, rheumatoid arthritis, or cancer.

77. Reticulocyte Count

A test that measures the number of young red blood cells (reticulocytes) in the blood, used to assess bone marrow function and red blood cell production.

78. Antithrombin III Deficiency

A rare inherited disorder that increases the risk of developing blood clots due to insufficient levels of antithrombin, a protein that inhibits clot formation.

79. Hemophilia B

A genetic bleeding disorder caused by a deficiency of clotting factor IX, leading to prolonged bleeding after injury or surgery.

80. Splenomegaly

An enlargement of the spleen, which can occur due to various conditions such as infections, liver disease, or blood cancers.

81. Neutrophil

A type of white blood cell that is the first line of defense against bacterial infections and plays a critical role in inflammation.

82. Basophils

A type of white blood cell that releases histamine and heparin during allergic reactions and inflammation.

83. Monocytosis

An increase in the number of monocytes (a type of white blood cell), often associated with chronic infections or inflammatory conditions.

84. Aplastic Anemia

A rare and serious condition where the bone marrow fails to produce enough blood cells, leading to anemia, infections, and bleeding.

85. Vitamin B12 Deficiency Anemia

A type of anemia caused by a lack of vitamin B12, which is essential for red blood cell production and nerve function.

86. Hemoconcentration

An increase in the concentration of blood cells and other components due to a reduction in plasma volume, often caused by dehydration.

87. Bleeding Time

A test that measures the time it takes for a small blood vessel to stop bleeding, used to evaluate platelet function and clotting ability.

88. Hematopoietic Stem Cell Transplantation

A medical procedure in which hematopoietic stem cells (from bone marrow or peripheral blood) are transplanted to treat blood cancers or bone marrow failure.

90. Coagulation Cascade

A complex series of events in the blood clotting process, where a series of clotting factors work together to form a blood clot.

91. Hemoglobinopathies

Inherited disorders that affect the structure or production of hemoglobin, such as sickle cell disease or thalassemia.

92. Hypereosinophilia

A condition characterized by an elevated number of eosinophils (a type of white blood cell), often seen in allergic reactions, parasitic infections, or certain blood cancers.



93. Sickle Cell Disease

A genetic disorder where the red blood cells are shaped like a crescent (sickle), leading to blockages in blood flow and causing pain, anemia, and potential organ damage.

94. Anemia of Chronic Disease

A type of anemia that occurs due to chronic illnesses such as infections, cancer, or autoimmune diseases, where the body has an impaired ability to produce red blood cells.

95. Thrombocytopenia

A condition characterized by a low platelet count, leading to an increased risk of bleeding or bruising.

96. Myeloproliferative Disorders

A group of disorders in which the bone marrow produces excessive amounts of blood cells, including conditions like polycythemia vera and essential thrombocythemia.

97. Leukocytosis

An increase in the number of white blood cells, often due to infections, inflammation, or leukemia.

98. Lymphoma

A type of cancer that begins in the lymphatic system, leading to the uncontrolled growth of lymphocytes (a type of white blood cell).

99. Hemostatic Disorders

Disorders that affect the ability of blood to clot properly, which can result in excessive bleeding or clotting. Examples include hemophilia and von Willebrand disease.

100. Iron Overload

A condition where the body accumulates too much iron, which can damage organs like the heart and liver. It is often seen in conditions like hemochromatosis.

101. Coagulation Profile

A set of blood tests used to evaluate the clotting ability of blood, including tests for prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen levels.

102. Stem Cell Transplantation

A procedure where hematopoietic stem cells from a donor are transplanted into a patient to treat blood cancers like leukemia or non-cancerous blood disorders like aplastic anemia.

103. Peripheral Blood Smear

A laboratory test that involves examining a sample of blood under a microscope to assess the number, shape, and size of blood cells.

104. Chronic Lymphocytic Leukemia (CLL)

A slow-growing cancer of the blood and bone marrow that affects lymphocytes, leading to an overproduction of abnormal white blood cells.

105. Thrombotic Thrombocytopenic Purpura (TTP)

A rare, potentially life-threatening blood disorder characterized by blood clot formation in small blood vessels, leading to low platelet counts, anemia, and organ damage.

106. Red Cell Distribution Width (RDW)

A measure of the variation in size of red blood cells, which can help diagnose various types of anemia.

107. Bone Marrow Failure

A condition in which the bone marrow does not produce enough blood cells, leading to anemia, bleeding, and infections.

108. Prothrombin Time (PT)

A blood test that measures how long it takes for blood to clot, used to evaluate the function of clotting factors.

109. Hematopoiesis

The process of blood cell production, which occurs in the bone marrow, including the production of red blood cells, white blood cells, and platelets.

110. Hemophilia A

A genetic bleeding disorder caused by a deficiency in clotting factor VIII, leading to prolonged bleeding after injury or surgery.

111. Factor V Leiden

A genetic mutation that increases the risk of blood clotting, particularly deep vein thrombosis (DVT) and pulmonary embolism.

112. Sickle Cell Trait

A genetic condition where an individual inherits one sickle cell gene and one normal gene, leading to the possibility of passing the sickle cell disease to offspring but not necessarily suffering from the disease themselves.

113. Tissue Factor

A protein present in cells that triggers the clotting process when blood vessels are injured. It plays a critical role in the coagulation cascade.



114. Hypoproliferative Anemia

Anemia caused by a failure of the bone marrow to produce enough red blood cells, often due to chronic diseases or bone marrow disorders.

115. Hematologic Malignancy

Cancer of the blood or bone marrow, including conditions such as leukemia, lymphoma, and myeloma.

116. Haptoglobin

A protein in the blood that binds to free hemoglobin released during red blood cell destruction, preventing kidney damage.

117. Monoclonal Antibodies

Laboratory-made antibodies that can mimic the immune system's ability to fight harmful pathogens, often used in the treatment of cancers like lymphoma or leukemia.

118. Folic Acid Deficiency Anemia

A type of anemia caused by a lack of folic acid (vitamin B9), which is essential for red blood cell production.

119. Hemoglobin S

A mutated form of hemoglobin found in individuals with sickle cell disease, which causes red blood cells to take on a crescent shape and leads to blockages in blood flow.

120. Blood Grouping

A test used to determine an individual's blood type (A, B, AB, or O) based on the presence of antigens on red blood cells, which is crucial for blood transfusions.

121. Reticulocyte Count

A blood test that measures the number of reticulocytes (immature red blood cells) in the blood, used to assess the bone marrow's ability to produce new red blood cells.

122. Immune Thrombocytopenic Purpura (ITP)

A condition in which the immune system destroys platelets, leading to easy bruising, bleeding, and low platelet counts.

123. Thrombotic Microangiopathy

A disorder characterized by the formation of small blood clots in the microvasculature, which can cause organ damage and low platelet counts.

124. Gene Therapy in Hematology

A technique being researched to treat genetic blood disorders like sickle cell disease and thalassemia by correcting or replacing defective genes.



125. Polycythemia

An increase in the number of red blood cells in the bloodstream, which can lead to thicker blood and an increased risk of clotting.

126. Granulocytes

A category of white blood cells that includes neutrophils, eosinophils, and basophils, involved in fighting infections and inflammatory responses.

127. Leukemia

A type of cancer that starts in blood-forming tissues, such as the bone marrow, and results in the production of abnormal white blood cells.

128. Bone Marrow Transplant (BMT)

A procedure used to replace damaged or diseased bone marrow with healthy stem cells from a donor, used to treat various hematologic disorders, including leukemia and lymphoma.

129. Serum Ferritin

A blood test that measures the level of ferritin, a protein that stores iron in the body. Low ferritin levels are a sign of iron deficiency.

130. DIC (Disseminated Intravascular Coagulation)

A serious condition in which small blood clots form throughout the bloodstream, leading to bleeding and organ damage due to clotting factor consumption.

131. Hematology-oncology

A subspecialty of hematology focused on diagnosing and treating blood cancers, including leukemia, lymphoma, and multiple myeloma.

132. Lymphocyte Subsets

Different types of lymphocytes, including T cells, B cells, and NK cells, which play crucial roles in the immune response and are often measured to assess immune function.

133. Thrombopoietin

A hormone that regulates the production of platelets by the bone marrow, essential for maintaining normal platelet levels.

134. Fibrinolysis

The process by which fibrin clots are broken down in the body, ensuring that blood clots do not persist beyond their necessary duration.



135. Hemoglobin A1c

A test that measures the average blood glucose levels over the past 2-3 months, commonly used to monitor diabetes.

136. Hypersplenism

A condition in which the spleen is overactive and removes blood cells from circulation too rapidly, leading to anemia, thrombocytopenia, and leukopenia.

137. Vitamin K Deficiency

A condition that affects the blood's ability to clot, often caused by insufficient vitamin K intake or malabsorption disorders.

138. Platelet Aggregation

The process by which platelets clump together to form a blood clot in response to injury. It is a critical step in wound healing and stopping bleeding.

139. Cytopenia

A deficiency in one or more types of blood cells (e.g., red blood cells, white blood cells, or platelets), which can be caused by various blood disorders or bone marrow failure.



References

1. Beutler, E. (1995). Glucose-6-phosphate dehydrogenase deficiency and other enzyme abnormalities. In *William's Hematology* (pp. 564-580). New York: Mac Graw Hill.
2. Dhermy, D. (1995). Erythrocyte membrane. Hemolytic anemias due to membrane abnormalities. In *Hematology of the Child* (pp. 147-158). Paris: Médecine-Sciences, Flammarion.
3. Di Buduo, C. A., Miguel, C. P., & Balduini, A. (2023). Inside-to-outside and back to the future of megakaryopoiesis. *Research and Practice in Thrombosis and Haemostasis*, 7(4), 100197. https://doi.org/10.1016/j.rpth.2023.100197
4. Henter, J. I., Arizo, M., Elinder, G., Imashuku, S., & Janka, G. (1998). Familial hemophagocytic lymphohistiocytosis. *Hematol Oncol Clin North Am*, 12, 417-433.
5. Metcalfe, D. D., Kim, D.-K., & Olivera, A. (2019). Overview of mast cells in human biology. In *Modern Hematology: Biology and Clinical Management* (2nd ed., pp. 1–22). Springer.
6. Metcalfe, D. D., Kim, D.-K., & Olivera, A. (2019). Overview of mast cells in human biology. In [Book Title] (pp. 1–22). First online: December 2, 2019.
7. Papo, T., Andre, M. H., Amoura, Z., Lortholary, O., Tribout, B., Guillevin, L., et al. (1999). The spectrum of acute hemophagocytic syndrome in systemic lupus erythematosus. *J Rheumatol*, 26, 927-930.
8. Palek, J., & Jarolim, P. (1995). Hereditary spherocytosis, elliptocytosis, and related disorders. In *William's Hematology* (pp. 536-555). New York: Mac Graw-Hill.
9. Avril, J. L., & Tardivel, R. (1996). Les complications bactériennes des transfusions sanguines. *Transfus Clin Biol*, 1, 43-49.



10. Duedari, N., Charpentier, F., Desaint, C., Norol, F., Rodet, M., & Wallet, P. (1992). Transfusion sanguine. In *L'Hématologie de Bernard Dreyfus* (pp. 1300-1342). Paris: Flammarion Médecine-Sciences.
11. Hoffbrand, A. V., Moss, P. A. H., & Pettit, I. E. (2006). *Essential Haematology* (5th ed.). Wiley-Blackwell. ISBN-13: 978-1-4051-3649-5. ISBN-10: 1-4051-3649-9.
12. Lefrère, F., & Hermine, O. (1998). Anémie hémolytique. *Encyclopédie Pratique de Médecine*, 1-1194. Elsevier, Paris.
13. Maloine, J., Garnier, M., & Delamar, M. (2008). *Hématologie essentielle* (29th ed.). Maloine. ISBN: 978-2-224-0312-4.
14. Sekeres, M. A., Kalaycio, M. E., & Bolwell, B. J. (Eds.). (2007). *Clinical Malignant Hematology*. McGraw-Hill Medical. https://doi.org/10.1036/0071436502.
15. Journal Officiel Algérien (2018, July 29). *N° 46 Art. 368-369.*
16. Fagiet, G. B. (2003). *Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management*.
17. Lefrère, F., & Hermine, O. (1998). Anémie hémolytique. *Encyclopédie Pratique de Médecine*, 1-1194. Elsevier, Paris.
18. Munker, R., Hiller, E., Glass, J., & Paquette, R. (Eds.). (2007). *Modern Hematology: Biology and Clinical Management* (2nd ed.). McGraw-Hill Medical.
19. Schmidt, O. H., & Lang, W. (1997). Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin. *New England Journal of Medicine*, 337, 1389.
20. Kubra, K., Huseyin, S. E., Suat, C., Cerigd, S., Serkan, Y., & Geyikoglu, F. (2019). The protective effect of propolis on rat ovary against ischemia-reperfusion injury: Immunohistochemical, biochemical, and histopathological evaluations. *Biomedicine & Pharmacotherapy*, 111, 631-637. https://doi.org/10.1016/j.biopha.2018.12.113



21. McNiece, I. K., & Briddell, R. A. (1995). Stem cell factor. *Journal of Leukocyte Biology*, *58*(1), 14-22. https://doi.org/10.1002/jlb.58.1.14

22. Kim, K. L., Seo, S., Kim, J. T., Kim, J., Kim, W., Yeo, Y., Sung, J.-H., Park, S. G., & Suh, W. (2019). SCF (Stem Cell Factor) and cKIT Modulate Pathological Ocular Neovascularization. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *39*(10).

Research sites used

https://doi.org/10.1161/ATVBAHA.119.313179

https://www.msdmanuals.com › accueil › troubles-du-sang

https://www.elsan.care › biologie-medicale › polynucle...

https://www.sysmex.fr › ... › Les paramètres du XN

https://www.redcrossblood.org › bl...

https://bloodcancer.org.uk › bloo...

https://pmc.ncbi.nlm.nih.gov › PM...

https://pubmed.ncbi.nlm.nih.gov › ...

https://www.stemcell.com › hemato...



https://geneglobe.qiagen.com › he...

https://www.news-medical.net › H...

https://www.msdvetmanual.com › ...

https://www.uottawa.ca › hematolo...